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ABSTRACT OF THE DISSERTATION
Focused ultrasound-mediated drug delivery to the brainstem
by
Dezhuang Ye
Doctor of Philosophy in Mechanical Engineering and Material science
Washington University in St. Louis, 2021
Professor Hong Chen, Chair
Brainstem gliomas are tumors that occur in the brainstem, the brain region that connects the
brain to the spinal cord and controls vital body functions. The critical anatomic location of the
brainstem precludes surgical intervention and limits the use of invasive therapeutic techniques.
Moreover, the frequently intact blood-brain barrier (BBB) of most brainstem gliomas prevents
therapeutic agents from reaching the diseased site. The currently available techniques for brain
drug delivery are either invasive (e.g., convection-enhanced delivery) or lack targeting to the
diseased site (e.g., intranasal brain drug delivery). Novel techniques that can noninvasively
overcome the BBB are critically needed for the treatment of brainstem glioma. Focused
ultrasound combined with microbubbles can noninvasively induce temporal BBB disruption
(FUS-BBBD) at the FUS-targeted brain region, allowing the trans-BBB delivery of
intravenously injected agents. Focused ultrasound-mediated intranasal delivery (FUSIN) is a
newly reported technique for brain drug delivery that integrates FUS and microbubbles to
enhance the accumulation of intranasally administered agents at the FUS-targeted brain location
with significantly lower systemic exposure than that of FUS-BBBD. The objective of this thesis
xix

was to evaluate the feasibility, safety, and efficacy of the two FUS-mediated techniques for drug
delivery to the brainstem with the ultimate goal of providing a novel strategy for the treatment of
brainstem gliomas.

The first part of the thesis focused on developing the FUS-BBBD technique for drug delivery to
the brainstem. Gold nanoclusters (AuNCs) were used as the model agents I demonstrated, for
the first time, the feasibility and safety of FUS-BBBD delivery targeting at brainstem on
wildtype mice. The FUS parameters were then optimized for maximizing the delivery to the
brainstem while limiting the leakage to the surrounding healthy brain tissue. Following that, I
used mice bearing diffuse intrinsic pontine glioma (DIPG), a high-grade glioma that spreads
throughout the brainstem, and showed that FUS-BBBD delivery achieved noninvasive and
localized delivery of intravenously (IV) injected AuNCs to the brainstem gliomas.

Despite the great promise of the FUS-BBBD, systemic drug toxicity associated with IV injection
remains a clinical challenge. FUSIN has the promise to not only locally enhance the drug
delivery to the brainstem but also minimize the systemic toxicity to the periphery organs. The
second part of this thesis demonstrated the feasibility and safety of FUSIN for non-invasive,
localized drug delivery to the brainstem with minimal systemic exposure. I found that FUSIN
achieved higher delivery efficiency and lower systemic exposure than FUS-BBBD in the
delivery of AuNCs to the brainstem.

The third part focused on applying FUSIN for delivering anti-programmed death-ligand 1
antibody (aPD-L1), an immunon checkpoints inhibitor, to the brainstem gliomas. I first
xx

characterized the dependency of FUSIN drug delivery outcome on several critical experimental
parameters, including the time interval between IN administration and FUS application, the FUS
pressure, and the sampling time (the waiting time after FUS treatment to sacrifice the mouse).
Uisngthe optimized parameters, aPD-L1 was then successfully delivered to the GL261 gliomas
implanted at the mouse brainstem.

Keywords: Focused ultrasound; Brain drug delivery; Blood-brain barrier; Intranasal, DIPG,
Brainstem
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Chapter 1: Introduction
1.1 Brainstem gliomas
Brainstem tumors refer to tumors in the brainstem. Brainstem gliomas are the most frequently
occurred brainstem tumors, which encompasses several tumor types with variable prognoses,
including pilocytic astrocytoma, fibrillary astrocytoma, anaplastic astrocytoma, glioblastoma
multiforme, and ganglioglioma [1]. The brainstem gliomas are generally occurring among
children population. They account for approximately 10–20% of all pediatric brain tumors.
Adults may also get the brainstem gliomas but with much less chance, accounting for around 1–
2% of adult brain tumor [2–4] . About 60–80% of all pediatric brainstem gliomas are diffuse
intrinsic pontine gliomas (DIPG), and most others include a spectrum of low-grade gliomas
(LGG) [5]. DIPG commonly arises at the pons, one major part of the brainstem, and typically
grows in a diffuse fashion among the normal cells within the brainstem. DIPG is associated with
a dismal prognosis of approximately 10 months with only 10% of patients living > 2 years
beyond the initial diagnosis. The LGG gliomas, including focal, dorsal exophytic, and
cervicomedullary gliomas, are encountered less often and have a better prognosis. However, if
untreated, they could also lead to progressive brainstem dysfunction and ultimately death.
The brainstem is the posterior part of the brain adjoining with the spinal cord. It is densely
packed ascending and descending tracts and nuclei carrying information to and from the brain.
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The three main parts, midbrain, pons and medulla, construct the brainstem and regulate basic
body functions, including blood pressure, respiration, and swallowing, as well as motor and
sensory functions [6]. Due to the critical structure and function of the brainstem, the treatment
strategies for brainstem gliomas require certain considerations [7]. Currently, the treatment of
low grade and slow-growing tumors is typically surgical removal if possible, followed by
chemotherapy and radiation therapy. DIPG can never be surgically removed due to its diffusive
nature. Radiation therapy is normally the only available option to temporarily slow down the
tumor from growing, although it is rarely curative. Chemotherapy can be combined with
radiation therapy or applied separately but has not been shown to improve outcome, partly due to
difficulties encountered in delivering active drugs adequately to the tumor site, as the blood-brain
barrier (BBB) of most DIPG is intact in more than 70% cases [8,9].

1.2 Blood-brain barrier (BBB)
The BBB is an important protective feature of the brain. It is a physiological, cellular, and
metabolic barrier that restricts the free movement of substances between the blood and the
extracellular fluid of the brain, limiting the access of pathogenic and other harmful bloodborne
substances [10]. The mature BBB can be divided into three layers. The first layer is endothelial
cells interconnected by tight junctions. The second layer is a continuous thick basement
membrane lining outside of the endothelial cells. And the third layer is made up of astrocyte end
feed and pericytes. The three layers form a barrier that only allows selected substances to cross
the BBB. Small, lipid-soluble molecules, for example, O2, CO2, ethanol, and steroid hormones,
can cross the BBB by passive diffusion. Ions, such as Na+, K+, Mg2+, Ca2+, Cl-, HCO3-, and H+,
can be actively transported across the BBB. Nutrients, such as glucose, amino acids, and ketone
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bodies, can reach the brain via specific transporters, and very few large molecules (e.g.,
neurotrophins and cytokines) can be uptake by the brain through receptor-mediated endocytosis.
However, most pharmaceutics, including 98% small-molecule drugs and 100% large-molecule
drugs administered in the systemic circulation, cannot pass through the BBB [11–13].
Several techniques have been proposed to overcome the BBB for brain drug delivery. For
example, convection-enhanced delivery directly infuses the drug into the desired location and
utilizes a pressure gradient at the infusion catheter tip to deliver therapeutics through the
interstitial spaces of the brain [14]. Although it achieved localized drug deposition, this delivery
requires surgical interventions to open a craniotomy window and insert catheters into the brain
and multiple catheters are needed to cover the whole brain, which poses even more risk. Drugs
can also be incorporated with nanocarriers to facilitate their transport across the BBB [15].
However, this method requires special designs of the carriers for achieving receptor-mediated
transcytosis. Moreover, the delivery could result in undesired biodistribution of both the drug
and nanocarriers to healthy brain region and other organs, such as liver, kidney, and heart.
Intranasal (IN) brain drug delivery directly delivers the drug from the nose to the brain,
bypassing the BBB without entering the blood circulation. It has been used to deliver a variety of
agents to the brain, including peptides, proteins, gene vectors, and stem cells [16–19]. However,
IN brain drug delivery remains limited to preclinical studies and small early-phase clinical trials
[20–23] mainly because the delivery is inefficient and not diseased-site targeted [21]. Focused
ultrasound (FUS) in combination with microbubbles (MBs) can non-invasively enhance the local
brain drug delivery either by intravenous injection for FUS-induced BBB disruption (FUSBBBD) or intranasal administration for FUS-mediated intranasal delivery (FUSIN). These two
techniques are the focus of this thesis.
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1.3 Focused ultrasound
Ultrasound is a mechanical wave which can be generated by applying an oscillating electrical
voltage to a piezoelectric material, such as certain crystals or ceramics, which respond with
mechanical deformation in proportion to the applied voltage. The expansion or contraction of the
material due to the electric potential causes the compression or rarefaction of its surrounding
medium, such as air or water. When an oscillating voltage produces pressure waves with
frequencies higher than the upper limit (~20 kHz) of human hearing frequency, it is ultrasound
[24]. Similar to light waves, ultrasound waves can be focused using either single element
concave transducers or electronically controlled phased arrays, comprised of large numbers of
much smaller piezoelectric transducers. By doing so, their energy can be concentrated up to 3
orders or magnitude into a small ellipsoid volume (~1 × 10 mm) at the focus, resulting in a high
intensity field at the focal region [25].
FUS can be divided into high-intensity focused ultrasound (HIFU) and low-intensity FUS,
depending on the output intensity of the FUS transducer. In this thesis, the term FUS refers to
low-intensity FUS. HIFU is sufficient to create a coagulation lesion in the brain with the goal of
developing a substantially less invasive way to create stereotactic brain lesions. The lowintensity FUS, when combined with MBs, can create several mechanical effects to facilitate the
localized delivery of therapeutics to the brain, including enhancing the intravenous injected
agents delivery to the brain by inducing the BBB disruption and increasing the locally
accumulation of the intranasal administered agents [26].

1.4 Microbubbles
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MBs are playing an important part in the FUS-BBBD and FUSIN drug delivery. They are 1-10
µm diameter lipid or protein-encapsulated gas spheres. MBs cavitate under ultrasound,
concentrating and amplifying the FUS energy at its targeted location. They significantly reduced
the FUS energy need for brain drug delivery, thereby limiting the risk of skull heating when
targeting brain tissues and making transcranial ultrasound treatments feasible. Acoustic
cavitation is typically categorized under two states: stable and inertial. Stable cavitation refers to
repetitive expansion and contraction of the microbubbles causes mechanical stimulation of the
blood vessels leading to transient, reproducible, BBB opening [27]. Inertial cavitation is typified
by bubble instability, often accompanied by strong inertial effects such as jetting, fragmentation
and shock-wave formation, which can cause cellular damage due to the high mechanical
pressures and lead to BBB disruption [28]. The mechanical index (MI) calculated by the peaknegative pressure of FUS divided by the square root of the center frequency has been commonly
used to predict the likelihood of cavitation. Recently, Bader et al. derived the cavitation index
(CI), defined as the peak-negative pressure divided by the center frequency, to gauge the
likelihood of subharmonic emissions due to microbubble stable cavitation [29,30]. Controlling
the FUS pressure can generally guide the bubble cavitation to achieve the optimal drug delivery
outcome without leading to damage of the brain.
Currently, there are three kinds of commercialized MBs, including Optison (GE Healthcare, WI,
USA), Definity (Lantheus Medical Imaging, MA, USA), and SonoVue (Bracco, Milano, Italy).
All have received FDA approval for diagnostic use as ultrasound image contrast agents and have
been used for FUS-induced BBB opening. Commercial MBs generally exceed 2 μm in diameter
and have an application window of 5–10 min. Although the MBs have different compositions,
half-lives, it has been shown that under identical MB concentrations, all those three kinds of
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bubbles induced similar and equivalent BBB-opening effects. However, the duration of the BBBopening effect has been found to depend on the degradation dynamics of each MB type [31]. In
addition to MB type, the concentration and volume of injected MBs produces various numbers of
nuclei for cavitation within the vasculature, which can also significantly affect the FUS-BBBD
[32]. In addition, previous studies have found that, compared with larger MBs (4–5 μm and 6–8
μm), MBs with a diameter of 1–2 μm offer significantly less permeability enhancement.
Increasing MB volume would increase the mechanical force acting on nearby cells, thus
expanding to a size sufficient to stimulate the vessel walls. Meanwhile, smaller (1–2 μm) MBs
have been reported to reduce recovery time following transient BBB opening [33,34].

1.5 FUS-induced blood-brain barrier disruption (FUSBBBD)
FUS in combination with MBs provide a non-invasive method that can transiently open the BBB
in highly targeted brain regions, promoting drugs in the circulation to be delivered into the brain.
The technique was first brought by Hynynen and his colleagues in 2001, hundreds of following
studies have been done to modify the method to produce safe, reproducible BBB opening by
combining low-intensity FUS with the delivery of intravenous-injected preformed MBs [35].
Although FUS-BBBD has been applied for brain drug delivery for decades and gains lots of
successes, the exact mechanisms remain unknown. MBs expansion and contraction induced
vessel wall displacement was proposed to be one potential mechanism [36,37]. MBs oscillation
motion can create microstreaming and generate shear stress and circumferential stress in the
vessel could also facilitate the delivery [38]. Inertial cavitation is associated with high velocity
microjetting, accompanying extreme local temperature and pressure rise was also suggested as a
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potential mechanism for BBB opening [39]. However, the inertial cavitation was correlated with
extravasation of red blood cells and edema, which is not preferred in brain drug delivery. The
current studies of FUS-BBBD can achieve the brain drug delivery without causing the
histological damage, also suggested that the IC is not necessary in the FUS-BBBD.
Besides the mechanical effects, several bioeffects were also proposed to be potential mechanisms
of the FUS-BBBD delivery. Increased vesicles were observed by electron microscopy by FUSBBBD, indicating that transcytosis with either carrier proteins or receptor mediated is
upregulated [40]. Caveolin proteins are significantly increased at 1 hour after FUS treatment
suggesting a role for caveolin-mediated endocytosis [41,42]. Downregulation of tight junction
proteins has shown that paracellular transport can occur following FUS treatment [43]. The
downregulation could return to pre-treatment levels by 4 hours confirmed that the FUS-BBBD is
a transient process [44]. The two-photon microscopy have been used to explore the mechanisms
of FUS-BBBD and suggested that both paracellular transport and transcellular transport were
existed during FUS-BBBD delivery [45,46].
FUS-BBBD has been used to deliver a wide range of therapeutic agents across the BBB to the
brain, including small molecule drugs [47], recombinant proteins [48–50], viruses [51,52], and
even cells [53,54]. This drug delivery technique has been investigated in multiple species,
prominently small rodent models with fewer studies in large animal models (e.g. swine, canine,
sheep, nonhuman primates (NHP)) and human subjects with targets in hippocampus, striatum,
thalamus, and tumor tissue. For small animal studies, MRI, ultrasound, and brain atlas-guided
FUS systems have been developed. A single transducer is generally used in small animal studies
which can cover a significant volume of tissue. Mice and rats were anesthetized and the hair on
the head was removed using an electric razor followed by depilatory cream. This step is
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important as the furs will influence the ultrasound wave penetration. FUS transducer then placed
on the animal head with its focal point targeting at the brain region where the drug supposed to
be delivered. Since 2015, the FUS-BBBD has started in early phase clinical trials on evaluating
the feasibility and safety of FUS-BBBD in patients with glioblastoma [55], Alzheimer’s disease
[56], and amyotrophic lateral sclerosis [57] etc. The experimental procedures for human and
large animals is similar as in small animal studies. Both single element transducer [58] and
multi-phased array device were used for treating large animal including human, which can
achieve more flexible target configurations with varying patterns of transducer alignment and
activated elements [56,59]. In human study, the clinical MRgFUS device can target brain regions
with sub-millimetric accuracy, using real-time feedback for monitoring and intraoperative image
guidance ultrasound. The goal was to maximally impact the targeted region and tissue while
minimizing interfaces with vascular structures and ventricles. The optimal ultrasound power for
BBB opening is determined via a ramp test. The ramp test involves applying short sonication of
incremental power until the cavitation threshold is detected on acoustic feedback from the target.

1.6 FUS combined with microbubble-mediated intranasal
(FUSIN)
FUSIN integrated FUS to locally enhance the accumulation of IN administered. IN drug
administration offers non-invasive delivery through the olfactory route, with direct access to the
brain. IN administration has been used for the delivery of various biologics, such as peptides,
proteins, chemotherapeutics, gene vectors, various nanoparticles, and stem cells, for the
treatment of brain diseases such as stroke, Parkinson’s’ disease, Alzheimer’s diseases, and
gliomas [60]. The advantages of IN delivery include bypassing the BBB, rapid delivery to the
brain, bypassing peripheral clearance, and decreased systemic toxicity. Despite all these
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advantages, IN brain drug delivery has yet to be effectively translated to clinical practice, and
remains limited to preclinical studies and small early-phase clinical trials mainly because of
inadequate drug transport to the affected brain tissues [61].
The nose-to-brain delivery mainly through the olfactory and trigeminal nerves that start from the
olfactory region and respiratory region and connected to brain. The olfactory mucosa is above
normal airflow pathways and contains neurons that directly connect the nasal cavity with the
brain. The trigeminal nerve extending from the nasal cavity to the brainstem. (Fig. 1.1). Upon
reaching the olfactory bulb (olfactory pathway) or brainstem (trigeminal pathway), INadministered agents rapidly [62] distribute throughout the brain along the cerebral perivascular
spaces (PVS)–thin fluid-filled channels surrounding cortical blood vessels down to the level of
microvessels [63]–and may be propelled through the PVS by bulk flow induced by the heartbeatdriven pulsation (expansion and contraction) of blood vessel walls, called “perivascular pump
effect”[63]. But the agents are subsequent confined within the PVS, thereby limiting their
abilities to reach diseased cells in the brain interstitial spaces [64]. All previous studies on
enhancing IN delivery efficiency to the brain concentrated on improving the agent absorption
across the nasal epithelium [65], such as the use of nasal absorption enhancer[66] or surfacemodified nanoparticles [67]. However, there is no clear improvement in the IN brain drug
delivery efficiency in the past two decades [68,69].
FUSIN takes advantages of the underutilized nasal route for direct nose-to-brain drug
administration, bypassing the BBB and minimizing systemic exposure to normal organs, and
employs focused ultrasound (FUS)-activated microbubbles to enable localized accumulation of
the administered drugs at the FUS-targeted brain location. FUSIN has been shown can
significantly enhance the accumulation of intranasal delivery agents in the FUS targeted caudate
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putamen and brainstem [70–73]. The mechanism under FUSIN has not been unveiled yet. Previous
work on ultra-high-speed photomicrography of microbubble dynamics in ex vivo microvessels
[74] observed that microbubble oscillations push and pull on the blood vessel, which leads to
expansion and contraction of the vessel and surrounding tissue. Based on the similarity of this
phenomenon with the perivascular pump effect, we hypothesized that the “microbubble pump
effect” may be the potentially enhance the IN delivery. Additionally, IN delivery followed by
FUS showed significant increase in drug delivery when compared with IN only, while the
pretreatment by FUS followed by IN did not significantly enhance IN delivery efficiency. This
indirectly supported that the “microbubble pump effect” , instead of enhancing the BBB
permeability, contributed to the enhanced drug delivery, as when drugs were administered after
FUS sonication, the microbubble pump could not affect the drug delivery outcome as the drugs
were not in the perivascular space when microbubbles were activated by the FUS.
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Figure 1. 1 Concept of focused ultrasound-mediated intranasal brain drug delivery (FUSIN)
technique. Intranasally administered agents can reach the brain through the olfactory nerve and
trigeminal nerve pathways and then distribute in the brain along the cerebral perivascular spaces
by the “perivascular pump effect.” FUS-activated microbubble (MB) oscillation may induce the
“microbubble pump effect,” leading to the enhanced transport of intranasally administered agents
at the FUS-targeted brain location.
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Chapter 2: FUS-BBBD for the delivery of
radiolabeled nanoclusters to the brainstem
2.1 Abstract
The goal of this study was to establish the feasibility of integrating focused ultrasound (FUS)mediated delivery of 64Cu-integrated gold nanoclusters (64Cu-AuNCs) to the brainstem for in
vivo quantification of the nanocluster brain uptake using positron emission tomography (PET)
imaging. FUS was targeted at the brainstem for the blood-brain barrier (BBB) disruption in the
presence of systemically injected microbubbles, followed by the intravenous injection of 64CuAuNCs. The spatiotemporal distribution of the 64Cu-AuNCs in the brain was quantified using in
vivo microPET/CT imaging at different time points post injection. Following PET imaging, the
accumulation of radioactivity in the brainstem was further confirmed using autoradiography and
gamma counting, and the gold concentration was quantified using inductively coupled plasmamass spectrometry (ICP-MS). We found that the noninvasive and localized BBB opening by the
FUS can successfully deliver the 64Cu-AuNCs to the brainstem. We also demonstrated that in
vivo real-time microPET/CT imaging was a reliable method for monitoring and quantifying the
brain uptake of 64Cu-AuNCs delivered by the FUS. This drug delivery platform that integrates
FUS, radiolabeled nanoclusters, and PET imaging provides a new strategy for noninvasive and
localized nanoparticle delivery to the brainstem with concurrent in vivo quantitative imaging to
evaluate delivery efficiency. The long-term goal is to apply this drug delivery platform to the
treatment of pontine gliomas.

12

2.2 Introduction
Pediatric brain tumors kill more children than any other cancers, including leukemia. Among all
pediatric brain tumors, diffuse intrinsic pontine glioma (DIPG) is the most common brainstem
tumor of childhood and the single greatest cause of brain tumor-related death in children [75,76].
The treatment outcomes of DIPG have not been improved for decades, which is associated with
two unique characteristics of DIPG. First, the brainstem is one of the major structures in the
brainstem that controls basic vital life functions, such as breathing, hearing, taste, balance, and
communication between different parts of the brain. The critical anatomic location of the
brainstem precludes surgical intervention and limits the use of other invasive therapeutic
techniques. Second, in contrast to gliomas elsewhere in the brain, which often have compromised
blood-brain barrier/blood-tumor barrier (BBB/BTB), the BBB/BTB in DIPG is frequently intact
as suggested by the lack of contrast enhancement after magnetic resonance imaging (MRI)
contrast agent administration [77]. Currently, ongoing phase I/II clinical trials seek to circumvent
BBB/BTB function in DIPG using convection-enhanced drug delivery [3]. However, the
invasive implantation of catheters for convection-enhanced drug delivery raises significant safety
concerns. Thus, there is a pressing need for the development of alternative, noninvasive
techniques for BBB/BTB disruption for efficient delivery of chemotherapy to the brainstem for
the treatment of DIPG.
Transcranial focused ultrasound (FUS) in combination with microbubbles has been established
as a promising technique for noninvasive and localized BBB opening. FUS concentrates
externally generated ultrasound waves through the intact scalp and skull onto cubic millimetersized regions up to ~10 cm deep into the brain, allowing highly precise and noninvasive targeting
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of focal brain locations. Microbubbles, gas-filled micron-sized bubbles coated by shells, are
constrained in the vasculature after intravenous administration, as their sizes are comparable to
red blood cells. When the microbubbles are exposed to the FUS, they undergo volumetric
oscillation, which generates mechanical forces on the endothelium and results in a transient
increase in the BBB permeability. The strategy of combining FUS with microbubbles for drug
delivery across the BBB was first reported more than a decade ago [35]. Subsequent studies in
rodent and non-human primates have confirmed that FUS can induce temporary BBB opening
without observable tissue damage or functional deficits even after repeated administration [78–
80]. Increased therapeutic efficacy of various agents delivered by the FUS technique has also
been demonstrated [81–83]. Despite the great advancement of the FUS technique, its application
has been focused on the treatment of diseases located within the cerebrum (e.g., glioblastoma
and Alzheimer’s disease). However, pediatric brain tumors are commonly located in the
cerebellum and brain stem, which are rare sites for adult brain tumors. The application of FUSenhanced drug delivery to these brain locations has not been studied [84].
Recently, there has been a growing interest in using FUS for the trans-BBB delivery of
nanoparticles, which takes advantage of the noninvasive and localized BBB disruption capability
of FUS and the unique characteristics of nanoparticles as multicomponent constructs containing
imaging, targeting, and therapeutic entities. For example, it was demonstrated that FUS
sonication enhanced the delivery of chemotherapeutic drug-loaded liposomes and significantly
hindered the brain tumor growth in a mouse model [85]. One study showed the successful transBBB delivery of a biodegradable polymeric nanoparticle that is capable of penetrating within the
brain microenvironment [86]. Magnetic nanoparticles were also delivered by FUS-induced BBB
opening, and the deposition of the magnetic nanoparticles at the targeted brain site was enhanced
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by magnetic targeting with concurrent MRI monitoring [82]. In another study, gold nanoparticles
were safely delivered to the tumor margins in a mouse brain tumor model [87]. Recently, lowdensity lipoprotein nanoparticles reconstituted with docosahexaenoic acid (DHA) were delivered
to the brain by the FUS-induced BBB opening technique and led to the enhanced delivery of
DHA in the exposure region of the brain [83]. Among all the previously reported studies, only
one study delivered radiolabeled-nanoparticles [88]. In that study, 111ln-labeled liposomes, which
were conjugated with human atherosclerotic plaque-specific peptide-1 (AP-1) and loaded with
doxorubicin, were imaged using single-photon emission computed tomography (SPECT), from
which the tumor-to-normal brain ratio of the liposome concentration was calculated. Recently,
ultrasmall nanoclusters have drawn significant attention for biomedical applications due to their
size-promoted clearance after systematic injection [89–93], and accurate tumor targeting as we
demonstrated in previous research [94]. Through direct 64Cu incorporation into the structure of
gold nanocluster (64Cu-AuNCs), quantitative pharmacokinetic analysis by PET imaging can be
performed to determine the penetration and retention of 64Cu-AuNCs in tissue.
The goal of this study was to demonstrate successful delivery of ultrasmall 64Cu-AuNCs in the
brainstem by FUS-mediated BBB opening and to quantify the in vivo spatiotemporal distribution
of 64Cu-AuNCs using PET imaging. We first investigated the feasibility of FUS-mediated
delivery of a model drug to the brainstem by disrupting the BBB. We then investigated the FUSmediated delivery of 64Cu-AuNCs to the pons and monitored the spatiotemporal distribution of
64

Cu-AuNCs with PET imaging. The successful delivery of 64Cu-AuNCs into the brainstem was

verified by autoradiography and gamma counting of ex vivo brain slices and ICP-MS
measurement of gold concentration in the brainstem. The data presented here demonstrate the
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feasibility of this combined approach for effective and quantitative delivery of 64Cu-AuNCs into
brainstem.

2.3 Materials and methods
Animals
All animal procedures for these experiments were reviewed and approved by the Institutional
Animal Care and Use Committee of Washington University in St. Louis in accordance with the
National Institutes of Health Guidelines for animal research. Adult male mice (C57BL/6, age 6
to 8 weeks, Charles River Laboratory, Wilmington, MA, USA) were divided into four groups:
Group 1 (n=3) evaluated the delivery of a model drug across the BBB into the brainstem after
FUS treatment; Group 2 (n=3) evaluated the safety of the FUS treatment; Group 3 (n=8) assessed
FUS-enabled delivery of 64Cu-AuNCs to the brainstem using in vivo microPET/CT imaging;
Group 4 (n=12) verified in vivo imaging results with ex vivo autoradiography, gamma counting,
and inductively coupled plasma mass spectrometry (ICP-MS).
FUS sonication
An ultrasound image-guided FUS system (VIFU 2000, Alpinion US Inc., Bothell, WA, USA)
was used for the sonication (Fig. 2.1A). The FUS transducer had a center frequency of 1.5 MHz,
a focal depth of 60 mm, an aperture of 60 mm, a circular central opening of 38 mm, and was
driven by a built-in signal generator. The transducer was connected to a 3D stage for positioning
(Velmex, Lachine, QC, Canada). The transducer was also attached to a water balloon filled with
degassed water to provide acoustic coupling. The water balloon was immersed in a degassed
water container, the bottom of which featured a window sealed with an acoustically and optically
transparent membrane (Tegaderm, 3M, St. Paul, MN, USA). A B-mode imaging probe (L8-14,
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working frequency 8-14 MHz, center frequency 12 MHz, Alpinion, Seoul, Korea) was inserted
into the FUS transducer opening and aligned with the focal plane. Mice were placed prone on a
heating pad with their heads immobilized by a stereotaxic frame (David Kopf Instruments,
Tujunga, CA, USA). The fur on the head was removed while the skull and the scalp remained
intact. The water container was placed on the mouse head and coupled with degassed ultrasound
gel.

Figure 2. 1 : (A) Illustration of the FUS treatment setup. (B) Illustration of FUS targeting of the
brainstem with the assistance of a grid. The grid was placed on top of the mouse head with the center of
the grid aligned visually with the lambda. B-mode images of the grid were obtained and reconstructed to
3D for the identification of the grid crossing point. The left brainstem was targeted based on its
stereotactic location in reference to the lambda. (C) 2D pressure map of the FUS beam at the axial focal
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plane. (D) Axial and (E) lateral pressure profiles across the focus. The directions of the axes (X, Y, and Z)
are added in (A) and (B) to help understand the positioning of C, D, and E with respect to the mouse.

The pressure amplitudes and beam dimensions of the FUS transducer were calibrated using a
needle hydrophone (Onda, CA, USA) in a degassed water tank before the experiment. The
pressures reported here were the measured hydrophone peak negative pressures with corrections
for mouse skull attenuation [95]. The pressure field measured in the axial plane is shown in
Figure 2.1B. The full width at half maximum (FWHM) of the axial beam (Figure 2.1C) and
lateral beam (Fig. 2.1D) were 6.04 mm and 0.62 mm, respectively.
Targeting the FUS focus at the brainstem was performed with the assistance of a grid. The grid
was positioned in the water container on top of the mouse head with the crossing point in
alignment with the lambda, an anatomic landmark on the skull and visible through the mouse
skin on the head. The B-mode imaging probe was used to scan through the grid and form a 3D
image of the grid using a customized Matlab (Mathworks inc., Natick, MA, USA) program. The
crossing point of the grid was then identified and used as the reference point for targeting the
FUS to the brainstem on the left side of the mouse brain based on the brainstems’ stereotactic
location relative to the lambda (0 mm frontal and 1.50 mm to the left). The depth of FUS focus
was adjusted to be 4.00 mm from the skull by measuring the distance from the skull on the Bmode images.
Size-selected microbubbles with a median diameter of 4–5 μm were prepared in-house according
to a previously described protocol [96] and diluted using sterile saline to a final concentration of
approximately 8×108 number of microbubbles per mL. The diluted microbubbles (volume = 25
μL) were administered through a bolus injection via the tail vein. Immediately after injection (~9
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s), pulsed FUS (center frequency 1.5 MHz; pressure 0.52 MPa; pulse length 0.67 ms; pulse
repetition frequency 5 Hz; duration 1 min) was applied to the left side of the brainstem. The
pressure reported here was the peak negative pressure measured in water with correction for
mouse skull attenuation (18%) [95].
A Texas red-tagged dextran (amount 2 mg, molecular weight 40 kDa, Invitrogen, Carlsbad, CA,
USA) was dissolved in 100 µL saline and co-injected with the microbubbles to mice in group 1.
The mean hydrodynamic diameter (

) of the dextran as measured using dynamic light

scattering (NanoZS, Malvern, Worcestershire, UK) was 4.10 nm. Microbubbles mixed with 100
µL saline were injected to the mice in group 2. The mice in the treatment subgroup of group 3
were injected with 64Cu-AuNCs mixed with 60 µL Evans blue at 1 h post FUS sonication. Evans
blue was used to provide a visual indication of the BBB opening location.
Fluorescence imaging and quantification
Mice in group 1 were transcardially perfused at 4 h post-FUS sonication, and their brains were
harvested. After overnight fixation in paraformaldehyde followed by cryoprotection with
sucrose, the brains were cut into transverse sections and imaged using a fluorescence microscope
(Axi-overt S100; Zeiss, Oberkochen, Germany). For each mouse, a customized Matlab program
was used to quantify the fluorescent signal in 15 sequential brain slices. Circles with a 2-mm
diameter were selected by the Matlab program on the left and right sides of the brainstem as the
regions of interests (ROIs). A circle was drawn outside of the brain for the calculation of the
background image intensity. The sum of the pixel intensities within each ROI was normalized by
the mean background image intensity of each slice. The average of the normalized intensities of
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the 15 sequential brain slices was calculated for the left- and right-side ROIs to represent the
amount of dextran delivered to the FUS-treated and non-treated brainstem, respectively.
Histological analysis
For mice in group 2, whole brain histologic examinations were performed using hematoxylin and
eosin (H&E) staining. The harvested animal brains were fixed in 4% paraformaldehyde,
embedded in paraffin, and sectioned horizontally at 6 µm thickness in 10 separate levels with
180 µm intervals between two adjacent levels. At each level, four sections were acquired and
stained with H&E. Histological evaluation was performed single blinded, by a trained observer
without knowledge of the location and parameters of sonication.
Synthesis and characterization of 64Cu-AuNCs
64

Cu-AuNCs were synthesized as described previously [93]. In a typical reaction, water (2.0

mL), HAuCl4 (10 mM, 376 µL), and 64CuCl2 (74 MBq) were mixed in a glass vial, followed by
the dropwise addition of m-dPEG®12-Lipoamide (MW = 750 Da, 10 mM, 400 µL). Sodium
borohydride (40 mM, 400 µL) was added to this mixture and stirred rapidly for 2 hours. The
64

Cu-AuNCs were purified using a centrifuge filter (Amicon, 10K). Radiochemical purity was

determined using silica impregnated iTLC paper with a mobile phase of 1:1 methanol: 10%
ammonium acetate. Transmission electron microscopy (TEM) of decayed nanoclusters utilized a
Tecnai G2 Spirit Transmission Electron Microscope operated at 120 kV (FEI, Hillsboro, OR).
Additionally, dynamic light scattering (DLS) and zeta potential measurements were measured
using Zetasizer Nano ZS from Malvern Instruments.
In vivo microPET/CT imaging of 64Cu-AuNCs kinetics in the brain
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Four mice in group 3 were treated with FUS followed by intravenous injection of 64Cu-AuNCs
[3.7 MBq (100 μci) in 100 μL of saline/mouse], while the other four mice in group 3 were
injected with the same amount of 64Cu-AuNCs without FUS treatment. MicroPET/CT scans
were performed on all mice using the Inveon PET/CT system (Siemens, Malvern, PA) at 1 h, 4
h, and 24 h post injection. The PET images were corrected for attenuation, scatter, normalization,
and camera dead time and co-registered with CT images. The amount of activity recorded at the
time of imaging was decay corrected for the time between 64Cu-AuNCs injection and imaging.
The PET images were reconstructed with the maximum a posteriori (MAP) algorithm and
analyzed using Inveon Research Workplace. The uptake of 64Cu-AuNCs in the brain was
calculated in terms of the percent injected dose per gram (%ID/g) of tissue in three-dimensional
regions of interest (ROIs) without the correction for partial volume effect.
64Cu-AuNCs

biodistribution

Following the 24 h PET scans, animals were sacrificed, and all organs of interest were collected,
weighed, and counted in a Beckman 8000 gamma counter (Beckman, Fullerton, CA). The count
rate (counts per minute, CPM) from each sample of tissue was corrected by automatic
background subtraction and decay corrected (compensated for the decay of 64Cu radioactivity
over time). The corrected CPM from each tissue sample was normalized both to the mass of the
tissue sample (in grams, g) and to the injected dose (ID). Thus, the relative concentration of
64

Cu-AuNCs in each tissue sample was calculated as %ID/g.

Ex vivo evaluation of FUS delivery of 64Cu-AuNCs
Of the 12 mice in group 4, nine were treated by FUS followed by intravenous injection of one of
three 64Cu-AuNCs concentrations: 3.7 MBq, 9.3 MBq, or 18.5 MBq. The FUS treatment
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protocol was the same as that described in section 2.2. The other four mice in group 4 were
intravenously injected with 3.7 MBq of 64Cu-AuNCs without FUS treatment.
All of the mice in group 4 were sacrificed at 24 h post injection. The excised brains were sliced
coronally into 2-mm sections using a brain matrix (RBM-2000C; ASI Instruments, Inc., MI).
The slices were placed on a phosphor-imaging plate for overnight exposure. The radioactivity of
the brain slices was detected by autoradiography using a Storm 840 Phosphorimager (GE,
Marlborough, MA). Then, slices containing the brainstem were cut into two halves to separate
the FUS-treated and non-treated sides. Gamma counting was performed for each piece of tissue
samples to detect the 64Cu radioactivity These samples were then digested using a high-pressure
microwave digestion system (Milestone Inc. Monroe, CT) and gold concentration in the digested
brain tissue samples was determined using ICP-MS (Elan DRC-e, PerkinElmer, Germany).
Additionally, livers from all mice were harvested and prepared to verify the correlation between
the detected 64Cu radioactivity by gamma counting and the gold concentration quantified by ICPMS.
Statistical analysis
Statistical analysis was performed using GraphPad Prism (Version 6.04, La Jolla, CA, USA).
Group variation was described as mean ± standard deviation. Differences among two groups
were determined using the unpaired two-tailed Student’s t-test. One-way ANOVA analysis
followed by a post-hoc Tukey’s test was used to exam differences among three groups. A P
value < 0.05 was considered to represent a significant difference. Linear curve fitting between
the gamma counting and ICP-MS results was carried out using GraphPad and the goodness of fit,
R2, was calculated.
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2.4 Results
FUS-mediated delivery of a model drug to the brainstem is precisely targeted and non-invasive
Figure 2.2A shows a representative fluorescence image of a horizontal slice of the hindbrain
containing the brainstem obtained from a mouse in Group 1. The fluorescently labeled dextran
was mainly accumulated in the FUS-treated region of brainstem with minimal signal observed in
the non-treated region. This enhanced delivery of dextran at the FUS-treated brainstem was
consistently observed within this group of mice. Quantification of the ex vivo brain slices found
that significantly (P <0.005) higher fluorescence intensity at the FUS-treated site than the
contralateral non-treated brainstem (Fig. 2.2B). The same brain structure in the contralateral
hemisphere was not sonicated and acted as a commonly used internal control for quantifying
FUS-induced trans-BBB delivery outcome [81,97,98]. Evaluation of brain slices did not show
any tissue damage induced by the FUS treatment at the histological level. Figures 2.2C and 2.2D
display representative H&E staining of a brain slice. No hemorrhage was observed when
comparing the stained slices from FUS-treated region and contralateral non-treated region.
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Figure 2. 2: (A) Illustration of the FUS treatment setup. (B) Illustration of FUS targeting of the pons, the
major part of the brainstem, with the assistance of a grid. The grid was placed on top of the mouse head
with the center of the grid aligned visually with the lambda. B-mode images of the grid were obtained and
reconstructed to 3D for the identification of the grid crossing point. The left pons/brainstem was targeted
based on its stereotactic location in reference to the lambda. (C) 2D pressure map of the FUS beam at the
axial focal plane. (D) Axial and (E) lateral pressure profiles across the focus. The directions of the axes
(X, Y, and Z) are added in (A) and (B) to help understand the positioning of C, D, and E with respect to
the mouse.

FUS-mediated delivery of 64Cu-AuNCs into the brainstem
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The representative transmission electron microscopy analysis of decayed 64Cu-AuNCs showed a
homogeneous size distribution, confirmed by DLS analysis (

= 5.60±0.50 nm, zeta potential =

-0.40±0.11 mV) (Fig. 2.3).

Figure 2. 3: Characterization of 64Cu-AuNCs. (A) Transmission electron microscopy image and (B)
dynamic light scattering histogram of 64Cu-AuNCs show the prepared 64Cu-AuNCs had uniform size
distribution.

The PET images obtained from the non-treated mice verified that 64Cu-AuNCs could not cross
the intact BBB (Fig. 2.4A). While the PET images acquired from the FUS-treated mice
demonstrated successful delivery of 64Cu-AuNCs at the FUS-treated brainstem (Fig. 2.4B).
Compared with the non-treated mice, FUS enhanced the delivery efficiency of 64Cu-AuNCs
within the targeted brainstem by 3.37, 3.03 and 4.76 folds at 1 h, 4 h, and 24 h, respectively (Fig.
2.4C). This observation confirmed that FUS could open the BBB in the FUS-targeted region,
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allowing the localized delivery of 64Cu-AuNCs into the brain tissue. The radioactivity retained
in the FUS-treated brainstem decreased from 1.85±0.15 %ID/g at 1 h, 1.52±0.09 %ID/g at 4 h, to
1.45±0.16 %ID/g at 24 h (Fig. 2.4D); while, the volume of brain tissues containing radioactivity
increased from 0.06±0.02 cm3 at 1 h, 0.10±0.02 cm3 at 4 h, to 0.14±0.02 cm3 at 24 h (Fig. 2.4E).
Significant differences in concentration and volume were found between 1 h and 4 h (P <0.01)
and 1 h and 24 h (P <0.05), while no significant difference was found between 4 h and 24 h (P
>0.05).
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Figure 2. 4: Representative PET/CT images of non-treated (A) and FUS-treated (B) mouse brains at 24 h
after intravenous injection of 64Cu-AuNCs. (C) Quantification of 64Cu-AuNCs brain uptakes in FUStreated mice and non-treated mice at 1 h, 4 h, and 24 h post. FUS-treated mice had significantly higher
brain uptake of the 64Cu-AuNCs at all three time points. Comparison of the 64Cu-AuNCs brain uptakes
(D) and diffusion volume (E) at 1 h, 4 h, and 24 h post injection for the FUS-treated mice. The amount of
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radioactivity retained in the mouse brains decreased over time but the diffusion volume increased over
time (*:P < 0.05, **: P < 0.01, ***: P < 0.005).

Autoradiography of ex vivo brain slices at 24 h post injection verified localized delivery of 64CuAuNCs to the FUS-targeted brainstem region (Fig. 2.5A). A corresponding photograph of the
slice is presented in Fig. 2.5B. Evans blue staining, which indicates the location of the BBB
opening, was observed mainly at the left side of the brain slice, which matched the strong
radioactive signals observed on the corresponding autoradiography slice. We compared the
radioactivity of the FUS-treated side with that of the contralateral non-treated side of the slices,
as well as radioactivity of non-treated mice with intravenous injection of the same concentration
of 64Cu-AuNCs (3.7 MBq). It was found that the radioactivity of the FUS-treated side was
2.02±0.26 fold higher than that of the non-treated side of the same brain and 3.03±0.63 fold
higher than that of the non-treated mice (Fig. 2.5C). A significant difference was observed
between the contralateral non-treated side and non-treated mice, suggesting that at 24 h post
injection the 64Cu-AuNCs diffused from the FUS-treated side to the contralateral non-treated side
due to the small volume of the mouse brain.
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Figure 2. 5: (A) Representative autoradiograph of 64Cu-AuNCs in coronal brain slices at 24 h postinjection, indicating the localized delivery of 64Cu-AuNCs inside the FUS-treated left side of the mouse
brain. (B) Photograph of the brain slice shown in (A). (C) Quantification of radioactivity uptake at the
FUS-treated left side, the contralateral non-treated right side of the brain slices, and the brain slices
prepared from non-treated mice. (*:P < 0.05, ****: P < 0.0001).

Figure 2.6 summarized the post-PET biodistribution profile of 64Cu-AuNCs, which was
performed at 24 h post injection of the 64Cu-AuNCs. The radioactivity determined in the liver
was 6.04±0.72 %ID/g and spleen was 0.78±0.19 %ID/g. We noted that the whole brain uptake of
the nanoclusters at the 24 h post injection (0.37±0.10 %ID/g) was less than that quantified based
on PET imaging at 24 h post injection (Fig. 2.4D), because the PET quantification was
performed within the FUS targeted region, instead of the whole brain as in the biodistribution
analysis.
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Figure 2. 6: Biodistribution of 64Cu-AuNCs measured at 24 h post-injection.

Previously, we reported the in vitro radiolabel stability of 64Cu integrated gold nanostructures
[30]. Herein, we performed ICP-MS measurement of the gold concentration in the same tissue
samples after radioactivity decay. As shown in Figure 2.7, in the representative brain and liver
specimens, the gamma counting data (CPM/g) showed good correlation to the gold
concentrations (μg/g).
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Figure 2. 7: Correlation between 64Cu radioactivity measured by gamma counting and Au concentration
measured by ICP-MS of the same (A) brain and (B) liver samples with different 64Cu-AuNCs
concentrations (3.7 MBq, 9.3 MBq, and 18.5 MBq, n=3/group).

2.5 Discussion
The vital location of the brainstem and the intact BBB constitute substantial obstacles to the
successful treatment of DIPG. Consequently, there is a critical need for noninvasive and
localized trans-BBB drug delivery techniques. As a first step toward the long-term goal of
developing a drug delivery platform for the treatment of DIPG, we investigated the feasibility of
FUS combined with microbubbles for noninvasive and localized delivery of 64Cu-AuNCs to the
brainstem of mouse brains. We also integrated the FUS delivery with PET imaging for in vivo
quantitative evaluation of the 64Cu-AuNCs delivery efficiency and spatiotemporal distribution.
This study is the first to demonstrate successful opening of the BBB in the brainstem by the FUS
technique, enabling trans-BBB delivery of nanoparticles to the brainstem [99]. To find the
precise targeting location for drug delivery to the brainstem, we started with using a 40 kDa
Texas-red labeled dextran as the model drug, which had a comparable mean hydrodynamic size
(

=4.10 nm) to that of the 64Cu-AuNCs (

=5.60 nm). We showed precise targeting of the left

brainstem (Figs. 2A) without indication of vascular or tissue damage (Figs. 2C and 2D). Since
the brainstem controls vital life functions, the parameters of FUS were chosen to avoid
hemorrhage or neuron damage in reference to previous studies [79,100]. Although not the focus
of this study, we monitored the behavior of the mice throughout the course of our experiments.
All treated mice recovered from anesthesia within 15 min after the FUS treatment was finished.
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After recovery, no gross changes in drinking, eating, walking, hanging, jumping, or grooming
were observed.
The FUS-induced BBB opening technique has been evaluated for the delivery of various
nanoparticles with

within the range of 10–200 nm, such as liposomes, polymer nanoparticles,

magnetic nanoparticles, lipoprotein nanoparticles, and gold nanoparticles. This study involved
the unique integration of the FUS technique with radiolabeled nanoclusters for brain drug
delivery. 64Cu-AuNCs are unique in that their size is much smaller than other nanoparticles. In
contrast to the organ uptake acquired with 27-nm 64Cu-AuNPs [101], the 6-nm 64Cu-AuNCs
showed significantly decreased uptake in blood (0.46 ± 0.04%ID/g vs. 5.95 ± 0.45 %ID/g), liver
(6.03 ± 0.72%ID/g, 42.9 ± 3.44 %ID/g), and spleen (0.78 ± 0.19%ID/g vs. 203 ± 11.1%ID/g),
suggesting the advantages of renal-clearable nanoclusters in reducing any potential toxicity
concerns. [21]. Meanwhile, in our previous study, we used fluorescently-labeled dextrans with
various hydrodynamic diameters (2.3 nm, 10.2 nm, 30.6 nm, and 54.4 nm) to evaluate the sizedependency of the FUS-mediated delivery of dextrans to the brain. We found that the smaller
dextrans could be delivered to the brain with higher efficiency than the larger dextrans. The
delivery of dextrans smaller than 30.6 nm was found to be safe without any detectable tissue
damage since lower acoustic pressure was needed for the delivery of smaller agents. In addition,
we found a direct correlation between particle size and delivery efficiency, with smaller particles
more effectively delivered across the BBB [100]. The successful delivery of large particles
requires higher acoustic energy, which was reported to be associated with tissue damages [9,13].
Thus, the small size of 64Cu-AuNCs makes them particularly well-suited for brainstem drug
delivery considering the specific location and vital function of the brainstem. Our preliminary
safety evaluation using H&E staining showed no histological-level tissue damage associated
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with the FUS treatment (Figs. 2C and 2D). Future study is needed to fully evaluate the short-term
and long-term safety of the FUS treatment in the brainstem at both histological and molecular
levels [102].
The unique advantage of nanomedicine enables the integration of therapy with imaging. PET
imaging of radiolabeled nanoclusters provides a noninvasive, highly sensitive, and quantitative
method for assessing the efficiency of nanoparticle delivery and their spatial distribution. Thus,
we used PET imaging for the in vivo real-time quantification of nanoclusters delivery kinetics.
Compared with the non-treated mice, FUS significantly enhanced the delivery efficiency of
64

Cu-AuNCs within the targeted brainstem (Figs. 2.4A, 2.4B, and 2.4C). The 64Cu-AuNCs

reached the highest concentration in the brainstem at 1 h post injection and then decreased over
time (Fig. 2.4D), which is consistent with our previous finding that the half-life of the 64CuAuNCs in blood is around 0.87 h [93]. The 64Cu-AuNCs that were retained in the brain tissue
diffused to the surrounding area over time (Fig. 2.4E). The ex vivo autoradiography verified
localized delivery of 64Cu-AuNCs at the FUS-treated region of the brainstem (Fig. 2.5A).
Gamma counting of ex vivo brain slices confirmed the successful delivery of 64Cu-AuNCs into
the brainstem following FUS treatment and found the ratio between the radioactivity of the
treated and non-treated mice were 3.03±0.63 (Fig. 2.5C). The strong linear correlation between
gamma counting of radioactivity and ICP-MS quantification of Au concentration shown in Fig.
2.7 confirmed the in vivo radiolabel stability of 64Cu for accurate measurement of 64Cu-AuNCs
organ distribution and uptake.
Although several imaging techniques have been used for in vivo imaging of FUS-induced BBB
opening, PET has not been used for the in vivo quantification of the FUS trans-BBB delivery
efficiency of nanoparticles. Our study confirmed that the in vivo PET imaging is a reliable
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imaging method for monitoring and quantifying FUS-enabled delivery of 64Cu-AuNCs in mice.
Several studies have reported in vivo PET imaging for the quantification of FUS-enhanced brain
delivery of radiolabeled small molecular weight tracers, such as 99mTcdiethylenetriaminepentaacetic acid (99mTc-DTPA) [103], integrin α2β1 [104], 2-amino-[311C]isobutyric acid ([3-11C]AIB) [105], and 18F-FDG [106]. Along with these previous studies,
the nanoclusters reported here may pave the way for the future development of theranostic PET
agent for imaging-guided FUS brain drug delivery.
This study has several limitations. First, only one group of FUS parameters was selected in
reference to previous publications and found to be effective and safe for the BBB opening.
Future studies will fully optimize the FUS treatment at the brainstem by exploring different FUS
parameters and evaluating the short-term and long-term safety associated with the treatment.
Second, 64Cu-AuNCs were injected 1 h post sonication due to the transportation of mice between
facilities. Future study will be performed by injecting 64Cu-AuNCs and microbubbles
simultaneously to improve the delivery efficiency. Third, normal mice were used to demonstrate
the feasibility of the proposed technique for the noninvasive and localized drug delivery to the
brainstem. Future studies will evaluate the efficacy of this technique using a mouse model of
pontine glioma. Fourth, 64Cu-AuNCs labeled with molecular targeting ligands can be developed
in the future to further improve tumor targeting.

2.6. Conclusion
This study demonstrates that FUS in combination with microbubbles can successfully delivery
64

Cu-AuNCs to the brainstem. The 64Cu-AuNCs delivery outcome can be quantified through in

vivo PET imaging. The successfully delivery was further validated by autoradiography, gamma
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counting, and ICP-MS. This nanomedicine delivery platform that integrates FUS, PET, and 64CuAuNCs offers a new strategy for noninvasive, localized, and quantitative nanomedicine delivery
to the brainstem.
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Chapter 3: FUS-BBBD Mediated Delivery of
Nanoclusters to Diffuse Intrinsic Pontine Glioma
3.1 Abstract
Diffuse intrinsic pontine glioma (DIPG) is an invasive pediatric brainstem malignancy
exclusively in children without effective treatment due to the often-intact blood-brain tumor
barrier (BBTB), an impediment to the delivery of therapeutics. Herein, we used focused
ultrasound (FUS) to transiently open BBTB and delivered radiolabeled nanoclusters (64CuCuNCs) to tumors for positron emission tomography (PET) imaging and quantification in a
mouse DIPG model. First, we optimized FUS acoustic pressure to open the blood-brain barrier
(BBB) for effective delivery of 64Cu-CuNCs to brainstem in wildtype mice. Then the optimized
FUS pressure was used to deliver radiolabeled agents in DIPG mouse. Magnetic resonance
imaging (MRI)-guided FUS-induced BBTB opening was demonstrated using a low molecular
weight, short-lived

68

Ga-DOTA-ECL1i radiotracer and PET/CT before and after treatment. We

then compared the delivery efficiency of

64

Cu-CuNCs to DIPG tumor with and without FUS

treatment and demonstrated the FUS-enhanced delivery and time-dependent diffusion of

64

Cu-

CuNCs within the tumor.

3.2 Introduction
Diffuse intrinsic pontine glioma (DIPG) arises in the pons, the major part of the brainstem, and is
a leading cause of pediatric brain tumor death. At diagnosis, the majority of patients are between
5 and 10 years old and have a median survival of less than 1 year [64,107]. Resection is not an
option because of the diffuse nature of the tumor and the critical function of the brainstem. Focal
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radiation is the standard of care treatment for children with DIPG, and the addition of
chemotherapeutic agents or small molecule inhibitors has failed to show an improvement in
survival over radiation alone in numerous clinical trials conducted over the past several decades
[3,108]. This may be due to ineffective drug delivery to DIPG, which often has an intact bloodbrain tumor barrier (BBTB), and other potential obstacles, such as the restricted diffusion of
drugs through the brain parenchyma [109]. Many methods have been developed to overcome the
obstacles presented by the BBTB and increase drug penetration, such as intra-arterial
administration of osmotic agents enabling temporary disruption of BBTB [110], convectionenhanced delivery that interstitially infuses drugs under a constant pressure gradient [111], and
laser interstitial thermotherapy that allows laser ablation of a tumor via insertion of an optical
fiber [112]. These techniques either lead to BBTB disruption in the whole brain, or are
detrimentally invasive. The combination of focused ultrasound (FUS) and microbubbles (MBs),
which enhances the BBTB permeability, has drawn great attention due to its non-invasive and
localized delivery abilities and minimal neuronal damage [26]. FUS non-invasively penetrates
the skull and focuses energy on a small region of millimeter-scale dimensions. MBs, which have
been used in the clinic as ultrasound contrast agents for imaging, are administered by intravenous
(IV) injection. Following injection, their relatively large size (1–10 μm) confines them to the
vasculature instead of naturally penetrating the BBTB. MBs amplify and localize FUS-mediated
mechanical effects on the vasculature through FUS-induced cavitation (microbubble expansion,
contraction, and collapse), which generates mechanical forces on the vasculature and transiently
increases the BBTB permeability. To better localize the FUS treatment, magnetic resonance
imaging-guided FUS (MRgFUS) treatment enables precise targeting and treatment planning, and
allows targeted delivery of various therapeutics without damaging surrounding healthy structures
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[113–115]. This integrated technology has progressed rapidly and led to numerous ongoing
clinical trials in brain cancer patients due to the feasibility and safety of FUS[26,55,116–118].
Nanostructures have been widely used for cancer research due to the versatile physicochemical
properties and multifunctionality for diagnosis, drug delivery, and treatment [119–121]. Through
the combination with FUS to break BBTB, a variety of nanostructures have been used for brain
tumor imaging and treatment with proven advantages in terms of local targeting and
multifunctional theranostics [122–125]. However, there are no applications in DIPG. Previously,
we reported the trans-blood–brain barrier (BBB) delivery of an ultrasmall gold nanocluster
(64Cu-AuNCs) to the brainstem of wild-type mice following FUS treatment [73,126,127], which
paved a path for imaging and treatment of DIPG. Herein, we first optimized the acoustic pressure
for effective and safe BBB opening. Following MRgFUS, we precisely targeted DIPG tumor in
brainstem at an early stage and validated the BBTB opening using positron emission
tomography/computed tomography (PET/CT). Using an ultrasmall and biodegradable copper
nanocluster intrinsically radiolabeled with 64Cu (64Cu-CuNC) as a model drug [128], we studied
the tumor delivery efficiency, intratumoral diffusion, and retention in a mouse DIPG tumor
model and laid the foundation for potential early diagnosis and treatment of DIPG (Fig. 3.1).

3.3 Materials and methods
The CCR2 peptide (LGTFLKC) was synthesized by CPC Scientific (Sunnyvale, CA). The 64Cu
(half-life = 12.7 h, β+ = 17%, β− = 40%) was produced at the Washington University Cyclotron
Facility.

68

Ga was generated form Galli Eo™

The synthesis and radiolabeling of

68

68

Ge/68Ga generator (IRE - IRE EliT, Belgium).

Ga-DOTA-ECL1i and

64

Cu-CuNCs were according to our

previous reports. Radiochemical purity was determined by instant radio-thin layer
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chromatography (radio-TLC) (Bioscan). All other solvents and chemicals were purchased from
Sigma-Aldrich, TCI America, or Fisher Scientific and were used as received. Water with a
resistivity of 18.2 MΩ cm was prepared using an E-Pure filtration system from Barnstead
International (Dubuque, IA).
Murine DIPG model.
All studies were conducted in compliance with the institutional animal care and use committee
(IACUC) guidelines of the Washington University. p53fl/fl Mice with Nestin promoter-driven
expression of Tv-a were a kind gift from Dr. Oren Becher, as were RCAS expression plasmids
encoding Cre, PDGF-B, and H3.3K27M. DF1 cells (ATCC CRL-12203) were cultured and
transduced with RCAS-Cre, RCAS-PDGF-B, or RCAS-H3.3K27M. When confluent, DF1 cells
were harvested and mixed 1:1:1 in 30 µL of medium (Total cell number 0.6~0.8 million). 1.2 µL
were stereotactically injected through a Hamilton syringe at 3 mm deep to lambda, into the
brainstem of post-natal day 7 pups. After recovery, pups were returned to their mother. Mice
were observed three times weekly for signs of tumor formation, which were most frequently
evident by four weeks post-injection.
T1-weighted and T2-weighted MRI scans were acquired at 3, 4 and 5 weeks post the virus
injection to monitor tumor growth and changes in neuroanatomy. The mice successfully
developed DIPG tumor were selected out for the study. The DIPG tumor mice were randomly
divided into two groups with and without FUS treatment.
MRIgFUS.
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During the MRIgFUS treatment, mice in the FUS group were anesthetized under 1% isoflurane
and placed in a small animal cradle with an MRI saddle coil (Image Guided Therapy, Pessac,
France) and stabilized with a bite bar and ear bars. The rectal temperature was monitored
throughout the experiment and maintained at 37°C. Ultrasound gel was carefully placed on top
of the mouse head after the hair was removed with a depilatory cream (Nair, Church & Dwight
Co., NJ, USA). Degassed water filled the FUS transducer’s water balloon to ensure sufficient
acoustic coupling.
The FUS transducer (Imasonics, Voray sur l’Ognon, France) was an 8-element annular array
with a center frequency of 1.5 MHZ. Prior calibration was performed in a water bath with a
capsule hydrophone (Onda HGL-0200, Sunnyvale, CA, USA). The axial and lateral full-width at
half-maximums were 5.5 mm and 1.2 mm, respectively. Pressure values were derated to account
for the 18% mouse skull attenuation. The FUS transducer was connected to an MRI-compatible
piezoelectric motor to mechanically move the transducer in the X and Y directions. The annular
array design allowed the FUS transducer to electronically steer the focus in the axial direction
(Z-axis) of the transducer.
Following the injection of Gadoterate Meglumine (Dotarem, 0.2 mL/kg) via tail vein, coronal
and axial T2-weighted MRI scans were acquired to image the mouse head and locate the
geometrical focus of the transducer (repetition time (TR): 2000 ms; echo time (TE): 52 ms; slice
thickness: 0.5 mm; in-plane resolution: 0.250.25 mm2; matrix size: 128128; averages: 4). The
MRI images were imported to a software program (ThermoGuide, Image Guided Therapy,
Pessac, France) to locate the focus of the transducer via 3-point triangulation. The transducer was
moved to the tumor center for FUS sonication. Microbubbles were prepared in-house to a mean
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diameter of 4-5 m and diluted using sterile saline to a final concentration of approximately
8×108 number of microbubbles per mL. The diluted microbubbles (volume ~ 25 μL) were
administered through a bolus injection via the tail vein and flushed with saline. FUS sonication
was performed 1 minute later (pressure: 0.61MPa, frequency: 1.5 MHz, pulse repetition
frequency: 5 Hz, duty cycle: 3.33%, pulse length: 6.7 ms, treatment duration: 1 min).
Micro-PET/CT imaging.
3, 4, and 5 weeks after tumor implantation, the DIPG mice were anesthetized and injected with
7.4 MBq

68

Ga-DOTA-ECL1i in 100 μL saline via the tail vein. Small animal PET scans were

performed on Inveon PET/CT system (Siemens, Knoxville, TN) at 1 h post injection (45-60 min
dynamic scan). After PET/CT imaging, the mice were rested to decay for 24 h and then treated
with FUS prior to the same PET/CT scan. Then the mice were randomly divided into FUS
treated and FUS non-treated groups. 3.7 MBq 64Cu-CuNCs was injected into all the mice via tail
vein and PET/CT imaging were collected at 24 h and 48 h post injection (60 min frame). The
micro-PET images were corrected for attenuation, scatter, normalization, and camera dead time
and co-registered with micro-CT images. The Inveon PET/CT scanner is periodically calibrated
using a normalization phantom of known activity concentration to ensure its quantitative
accuracy. Micro-PET images were reconstructed with the maximum a posteriori (MAP)
algorithm and analyzed using Inveon Research Workplace software. Tumor uptake was
calculated in terms of the percent injected dose per gram (%ID/g) of tumor tissue in threedimensional ROIs without the correction for partial volume effect.
Autoradiography.
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The mice were transcardially perfused and the brainstem were collected and sliced immediately
following the last PET/CT scan. The slices were covered by a phosphor-imaging film plate and
exposed overnight prior to imaging with a GE Typhoon FLA 9500 Biomolecular Imager.
Immunohistochemistry of tumor tissues.
After autoradiography, the mouse brainstems were fixed in 4% paraformaldehyde overnight,
followed by cryoprotection with sucrose. Then the brain slices were embedded in paraffin,
sectioned coronally into 15 µm thick sections and stained with H&E. Specifically, the slices
were deparaffinized, rehydrated, then stained by Hematoxylin followed by Eosin. After staining,
the sections were dehydrated and sealed with cover slips for image. Histological evaluation was
performed single-blinded by a trained observer without knowledge of the location and
parameters of sonication.
Statistical analysis.
Statistical analysis was performed using GraphPad Prism (Version 7.03, La Jolla, CA, USA).
Group variation was described as mean ± standard deviation. Differences among two groups
were determined using the unpaired two-tailed Student's t-test. A P value < 0.05 was considered
to represent a significant difference.

3.4 Results and Discussion
The effective trans-BBTB delivery of nanoclusters is mainly affected by both physicochemical
properties of nanoclusters and FUS parameters for BBTB opening. Based on our previous report
[126,128], we optimized the construction of

64

Cu-CuNCs with ultrasmall hydrodynamic sizes

(5.6 ± 1.5 nm) for effective renal clearance and neutral charge (zeta potential= -0.04 ± 0.12 mV)
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for optimal biodistribution (Table 3.1). We next studied the effect of varying FUS acoustic
pressures on BBB opening by PET imaging of

64

Cu-CuNCs in wildtype mice. Building on our

previous study [98], we targeted FUS on the left brainstem of C57BL/6 mice (n = 4 – 5) with
FUS pressures of 0.28, 0.61, 0.72 and 0.85 MPa prior to intravenous injection of

64

Cu-CuNCs.

PET/CT images demonstrated clear radioactive signals at the left brainstem for 0.61, 0.72 and
0.85 MPa at 24 h post-injection, while there was negligible uptake of

64

Cu-CuNCs at brainstem

treated with 0.28 MPa FUS pressure (Fig. 3.1). Quantitative analysis at 24 h in mice treated with
0.28 MPa FUS pressure showed

64

Cu-CuNCs uptake of 0.37 ± 0.02 percent injection dose per

gram (%ID/g) (n = 4) at the treated left brainstem and 0.34 ± 0.04 %ID/g (n = 4) at the nontreated right brainstem, while the background blood retention in the brainstem of mice without
FUS treatment was 0.42 ± 0.06 %ID/g (n = 4), demonstrating the ineffectiveness of BBB
opening under 0.28 MPa FUS treatment. However, mice treated with 0.61, 0.72 and 0.85 MPa
FUS showed significantly increased brainstem uptakes of 1.11 ± 0.46%ID/g (n = 5, P<0.01),
1.45 ± 0.36 (n = 4, P<0.0001), and 1.84 ± 0.21 %ID/g (n = 4, P<0.0001), respectively, at the
treated left brainstem. Interestingly, we also observed increased

64

Cu-CuNCs uptake at the non-

treated right brainstem in mice treated with 0.72 MPa and 0.85 MPa pressures, suggesting a
higher level of BBB disruption by elevated FUS pressure, which was consistent with our
previous report (Fig 3.1b). However, there was no significant difference in the ratios of uptake in
treated left vs non-treated right brainstem among the mice treated with 0.61, 0.72 and 0.85 MPa
FUS pressures (Fig 3.1c), showing similar treated/non-treated contrast of the three acoustic
pressures. Therefore, to minimize safety concerns while still obtaining sufficient delivery
efficiency, we opted to use 0.61 MPa FUS pressure as optimal for DIPG tumor imaging in this
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study. In addition, our previous studies have verified that 0.61 MPa FUS pressure resulted in no
tissue damage in the brain.

Figure 3. 1: (a) In vivo PET/CT images of 64Cu-CuNCs without FUS treatment and under 0.28 and 0.61
MPa FUS pressure in WT mice at 24 h post IV injection. (b) Quantitative analysis of 64Cu-CuNC uptake
in FUS-treated left brainstem and nontreated right brainstem of WT mice under 0.28, 0.61, 0.72, and 0.85
MPa FUS pressures and the brainstem without FUS treatment in WT mice. (c) Uptake ratios of treated
sites vs nontreated sites of the FUS-treated mice under different pressures (***p < 0.001, ****p <
0.0001, n = 4–5).
Table 3. 1: Characterization of CuNCs

Core size (diameter / nm)

Hydrodynamic diameter / nm

Zeta potential

2.0 ± 0.4

5.6 ± 1.5

-0.04 ± 0.12
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Next, we applied FUS to an established RCAS/TVA DIPG model involving overexpression of
the platelet-derived growth factor B (PDGFB) and introduction of H3.3K27M mutation into
nestin positive neural progenitors [129]. The anatomic characterization of tumor progression was
characterized by MRI and histological variation was assessed by hematoxylin and eosin (H&E)
staining. At 3 weeks, MRI showed nearly undetectable signal in both T1-weighted and T2weighted contrast enhanced images (Fig. 3.2a). However, H&E staining of collected specimens
revealed the presence of tumor cells within brainstem indicating the development of early tumors
(Fig. 3.2b) [130]. In comparison, contrast enhanced T1-weighted and T2-weighted images
demonstrated significant hyperintensity in the brainstem of 4-week-old mice (Fig. 3.2c),
indicating the significant invasion of tumors which was confirmed by the H&E staining of
brainstem sectioned from 4-week-old mice (Fig. 3.2b and 3.2d). Importantly, after FUS
treatment at the 3-week-old DIPG mice, enhanced intensity was observed at the position of
tumors in contrast enhanced MR images, which indicated the precisely targeting of the FUS to
the tumor sites that allowed the penetration of contrast agent through the broken BBTB (Fig 3.5).
This showed the potential efficacy of MRgFUS to delivery therapeutics for early intervention of
DIPG.
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Figure 3. 2: Comparison of contrast enhanced T1 and T2 weighted MRI images of (a) 3-week-old DIPG
mouse and related (b) H&E staining with MRI images at (c) 4-week-old DIPG mice and (d) H&E
staining.

To further confirm the opening of BBTB for early detection and treatment of DIPG, PET/CT
evaluation with/without FUS in the same mice was conducted using a short-lived radioisotope
68

Ga (T1/2 = 67.7 mins) labeled hydrophilic radiotracer, 68Ga-DOTA-ECL1i (MW=1375.7 Da), in

DIPG mice [131]. The rapid decay of

68

Ga enabled the comparison of the FUS treatment effect

in the same mouse in a span of 2 days. Specifically, three-week-old DIPG mice without FUS
treatment were injected intravenously with 7.4 MBq

68

Ga-DOTA-ECL1i via tail vein and

scanned with PET/CT at 1 h post injection, which showed no tracer uptake within brainstem
(Fig. 3.3a). After the decay of 68Ga, the same mice were treated with MRgFUS the next day prior
to a second 68Ga-DOTA-ECL1i PET/CT scan. As shown in Figure 3.3a, significant PET signals
were determined in the brainstem of mice with FUS treatment. Quantification showed that 68GaDOTA-ECL1i uptake in brainstem of treated mice (1.25 ± 0.53 %ID/g, n = 4) was approximately
46

2-fold higher than that acquired in non-treated mice (0.42 ± 0.22 %ID/g, n = 4, p<0.01), which
demonstrated the effectiveness of MRgFUS for opening the BBTB in the setting of DIPG (Fig.
3.3b).

Figure 3. 3: (a) In vivo PET/CT images and (b) the quantitative tumor uptake of 68Ga-DOTA-ECL1i in
3-week-old DIPG tumor mice with and without FUS treatment at 1 h post IV injection (**p < 0.01, n =
4).

We next analyzed the effect of FUS on

64

Cu-CuNCs accumulation and distribution within

brainstem in 3 and 4-week old DIPG mice using PET/CT imaging. Mice were randomized into
FUS treated and non-treated groups. As shown in Figure 3.4a, a strong PET signal was evident in
the brainstem of both 3 and 4-week-old DIPG mice at 24 and 48 h post injection of 64Cu-CuNCs.
Quantitative analysis showed similar tumor uptakes of 2.68 ± 0.20 %ID/g (n = 5) and 2.73 ± 0.18
%ID/g (n = 5) at 24 and 48 h post injection for FUS treated 3-week-old mice, values which were
significantly higher than those in untreated mice (Fig. 3.4b, p<0.0001, n = 6). Additionally, the
distribution volume of radioactive signal in the brainstem increased from 21.90 ± 2.24 mm3 to
34.4 ±2.22 mm3 between 24 and 48 hours (Fig 3.4c, p<0.01, n = 5 for both), suggesting the
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dynamic diffusion of

64

Cu-CuNCs within tumors, consistent with our previous report [126].

Furthermore, ex vivo autoradiography performed immediately after PET/CT imaging clearly
showed distribution of

64

Cu-CuNCs within the tumor in the FUS treated mice while minimal

retention was observed in the brainstem of mice without FUS treatment, confirming the PET data
(Fig. 3.6). The similar tumor uptakes between the 24 and 48 h time points may be attributed to
the closing of the transiently disrupted BBTB within a few hours of treatment [132]. The
prolonged intra-tumoral retention and dynamic diffusion of nanoclusters could have therapeutic
benefit if they were loaded with anti-tumor agents.

Figure 3. 4: In vivo PET/CT images, quantification of tumor uptake, and intratumoral distribution
volumes of 64Cu-CuNCs at 24 and 48 h post IV injection in (a–c) 3-week-old and (d–f) 4-week-old DIPG
mice (***p < 0.001, ****p < 0.0001, n = 3–6).
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In the 4-week-old tumor mice, tumor uptakes showed similar profiles to those at 3 weeks with
2.98 ± 0.62 %ID/g and 2.64 ± 0.26 %ID/g determined in the brainstem at 24 and 48 h post
injection (Fig. 3.4d and 3.4e, p<0.0001, n = 3). However, the diffusion of the nanoclusters
showed approximately two-fold increase from 24 h (29.3 ± 3.32 mm3, n=3) to 48 h (73.27 ± 4.74
mm, n=3, p<0.001) (Fig. 3.4f). This could be a result of diminishing tumor integrity over time,
resulting in a leakier tumor structure compared to DIPG tumors at 3 weeks, while still
maintaining BBTB integrity that excludes the permeation of the nanoclusters. This retaining
integrity of BBTB in 4-week-old mice was confirmed by the low signal in the non-treated mice,
whose tumor uptake was comparable to the blood retention of circulating

64

Cu-CuNCs in non-

treated 3-week-old DIPG mice. Moreover, at late stage of this DIPG model (5-week-old), due to
the deterioration of BBTB [133],

64

Cu-CuNCs accumulation was observed even without FUS

treatment (Fig. 3.7), which was further confirmed by T1 and T2 weighted MR images (Fig. 3.8).
Interestingly, in contrast to the reported low tumor uptake of

89

Zr-bevacizumab in DIPG mice

with disrupted BBTB, our combined strategy demonstrated significantly enhanced tumor
delivery, diffusion and retention of

64

Cu-CuNCs as a model-drug in DIPG mice, indicating the

unique advantages of our ultrasmall nanoclusters.
In comparison with other trans-BBB strategies, the MRgFUS demonstrated non-invasive
disruption of BBTB and effectively deliver the radiolabeled

64

Cu-CuNCs to the tumor with

minimal normal tissue damage. The use of ultrasmall nanoclusters could facilitate the penetration
of BBTB, but also is susceptible to rapid renal clearance, which further reduced the toxicity.
Furthermore, the biodegradability of the CuNCs could promote in situ drug release, showing
potentially enhanced treatment and reduced systemic toxicities. However, there are also some
limitations in our strategy. The safety evaluation of the study has only been accessed by H&E.
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Future studies are needed to carefully evaluate the safety related to inflammatory response due to
the FUS-BBTB disruption, moreover, although we have reported the minimal toxicity of CuNC,
a more organ-specific evaluation needs to be conducted on brain. Additionally, the

64

Cu-CuNC

used for this proof-of-concept study was a non-targeted nanocluster. Future studies need to focus
the PDGFB targeted approach. Also, we need to optimize the chemodrugs loading capacity of
PDGFB targeted CuNCs to assess DIPG treatment efficiency.

Figure 3. 5: Contrast enhanced T1-weighted MRI images in 3-week-old DIPG mice before and after FUS
treatment. Signals in yellow circles after treatment shows enhanced contrast. A. Coronal view, B.
Transverse view.
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Figure 3. 6: Autoradiography images and quantification of brainstem in the 3-week-old DIPG mice with
and without FUS treatment after PET imaging of 64Cu-CuNCs.

Figure 3. 7: In vivo PET/CT image of 5-week old DIPG mice at 24 h post 64Cu-CuNCs injection with and
without FUS treatment.
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Figure 3. 8: Contrast enhanced MRI images in 5-week-old DIPG mice

3.5. Conclusion
In summary, we examined the optimal FUS pressure to open BBB of naive mice for effective
delivery of 64Cu-CuNCs to brainstem. Using a hydrophilic, short-lived PET tracer, 68Ga-DOTAECL1i, we demonstrated the effectiveness of MRgFUS to precisely target the brainstem and
open the BBTB for potential drug delivery. Following MRgFUS treatment,

64

Cu-CuNCs

exhibited significant tumor uptake, dynamic distribution within tumors, and prolonged intratumoral retention within DIPG tumors. Together, these findings suggest that FUS-enhanced
delivery of biodegradable nanoclusters may provide a much-needed advancement in the
treatment of DIPG.
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Chapter 4: FUSIN delivery of gold nanoclusters
to the brainstem
4.1 Abstract
Focused ultrasound combined with microbubble-mediated intranasal delivery (FUSIN) is a new
brain drug delivery technique. FUSIN utilizes the nasal route for direct nose-to-brain drug
administration, thereby bypassing the blood-brain barrier (BBB) and minimizing systemic
exposure. It also uses FUS-induced microbubble cavitation to enhance transport of intranasally
(IN) administered agents to the FUS-targeted brain location. Previous studies have provided
proof-of-concept data showing the feasibility of FUSIN to deliver dextran and the brain-derived
neurotrophic factor to the caudate putamen of mouse brains. The objective of this study was to
evaluate the biodistribution of IN administered gold nanoclusters (AuNCs) and assess the
feasibility and short-term safety of FUSIN for the delivery of AuNCs to the brainstem. Three
experiments were performed. First, the whole-body biodistribution of IN administered 64Cualloyed AuNCs (64Cu-AuNCs) was assessed using in vivo positron emission
tomography/computed tomography (PET/CT) and verified with ex vivo gamma counting.
Control mice were intravenously (IV) injected with the 64Cu-AuNCs. Second, 64Cu-AuNCs and
Texas red-labeled AuNCs (TR-AuNCs) were used separately to evaluate FUSIN delivery
outcome in the brain. 64Cu-AuNCs or TR-AuNCs were administered to mice through the nasal
route, followed by FUS sonication at the brainstem in the presence of systemically injected
microbubbles. The spatial distribution of 64Cu-AuNCs and TR-AuNCs were examined by
autoradiography and fluorescence microscopy of ex vivo brain slices, respectively. Third,
histological analysis was performed to evaluate any potential histological damage to the nose and
53

brain after FUSIN treatment. The experimental results revealed that IN administration induced
significantly lower 64Cu-AuNCs accumulation in the blood, lungs, liver, spleen, kidney, and
heart compared with IV injection. FUSIN enhanced the delivery of 64Cu-AuNCs and TR-AuNCs
at the FUS-targeted brain region compared with IN delivery alone. No histological-level tissue
damage was detected in the nose, trigeminal nerve, and brain. These results suggest that FUSIN
is a promising technique for noninvasive, spatially targeted, and safe delivery of nanoparticles to
the brain with minimal systemic exposure.

4.2 Introduction
The development of effective therapies for central nerval system (CNS) diseases is often
challenged by the blood-brain barrier (BBB), which prevents most therapeutic compounds from
reaching the brain at the therapeutic level [134]. Current clinical strategies to circumvent the
BBB are either invasive (e.g., Gliadel wafers, intrathecal injection, and convection-enhanced
delivery) or lack specific targeting to the diseased site (e.g., hyperosmolar disruption using
mannitol and intranasal brain drug delivery) [135]. The use of focused ultrasound (FUS) and
microbubbles to enhance the BBB permeability is a recently developed technique for
noninvasive and localized delivery of intravenously (IV) injected drugs [114,136]. However, the
goals of drug delivery are not only to increase the local drug delivery efficiency but also to
reduce systemic toxicity. Despite the great promise of the FUS-induced BBB opening technique,
systemic drug toxicity associated with IV injection remains a clinical challenge. Brain drug
delivery strategies that can circumvent the BBB for noninvasive and localized drug delivery with
minimized systemic exposure are greatly needed to improve the treatment of CNS diseases. FUS
in combination with microbubble-mediated intranasal delivery (FUSIN) has the potential to
address this need. FUSIN is a novel technique first introduced by Chen and Konofagou in 2014
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[96]. It utilizes the nasal route for direct nose-to-brain drug administration, thereby bypassing the
BBB and minimizing systemic exposure. It also uses FUS-induced microbubble cavitation to
enhance the transport of IN administered agents to the FUS-targeted brain location.
The IN route can deliver therapeutic agents directly from the nose to the brain through the
olfactory and trigeminal nerve pathways, bypassing the BBB and minimizing systemic exposure
[60]. Direct IN delivery of therapeutics to the brain was first proposed in the 1980s [137]. The
exact mechanisms underlying IN brain drug delivery are not entirely understood; however, two
pathways have been identified: olfactory nerve pathway and trigeminal nerve pathway [60]. IN
administered therapeutics can be transported from the nasal cavity to the brain along the
olfactory nerve and trigeminal nerve, which innervate the epithelium of the nasal passages and
enter the brain in the olfactory bulb and brainstem, respectively. Once inside the brain entry
points (i.e., olfactory bulb and brainstem), the IN administered agents are distributed in the
whole brain along the cerebral perivascular spaces – thin annular regions surrounding the blood
vessels – and may be propelled through the perivascular spaces by heartbeat-driven pulsations of
the blood vessel walls, called the “perivascular pump effect” [138]. A wide-range of
therapeutics, such as peptides, proteins, gene vectors, and stem cells, have been successfully
delivered to the brain through IN administration and have shown efficacy in treating CNS
diseases in small animal models [16–19]. IN insulin delivery for the treatment of patients with
Alzheimer’s disease has been tested in early-phase clinical trials [139,140]. Recently,
formulations have been developed to further enhance the nose-to-brain transport efficiency,
mainly with the use of nanoparticles as drug carriers [65,141,142]. However, IN brain drug
delivery remains limited to preclinical studies and small early-phase clinical trials [20–23]
mainly because the delivery is inefficient and not diseased-site targeted [21].
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Unlike the more established FUS-induced BBB opening technique for trans-BBB delivery of
therapeutics in the systemic circulation, FUSIN uses FUS to activate microbubbles at a targeted
brain location to enhance the local accumulation of IN administered agents that are already
beyond the BBB. Previous studies showed that FUSIN enhanced the delivery of IN-administered
dextran and a protein drug (brain-derived neurotrophic factor, BDNF) at the FUS-targeted
caudate putamen of mouse brains [70,96]. Based on our previous work on ultra-high-speed
photomicrography of microbubble dynamics in ex vivo microvessels [37], we observed that
microbubble oscillations push and pull on the blood vessel, which leads to expansion and
contraction of the vessel and surrounding tissue. Based on the similarity of this phenomenon
with the perivascular pump effect, we hypothesized that the “microbubble pump effect” may be
the potential mechanism for FUSIN. This mechanism was indirectly verified by comparing the
delivery efficiency of FUS sonication before IN administration (without the microbubble pump
effect) to FUS after IN administration (with the microbubble pump effect) [70]. It was found that
significant enhancement was observed only when FUS sonication was performed after IN,
suggesting that the microbubble pump effect contributes to FUSIN.
The objective of this study was to evaluate the biodistribution of IN administered gold
nanoclusters (AuNCs) and assess the feasibility and short-term safety of FUSIN for the delivery
of AuNCs to the brainstem.
AuNCs were selected as the model agent. Recently, ultrasmall nanoclusters have drawn
significant attention for biomedical applications due to their size-promoted clearance after
systematic injection [89–93], and accurate tumor targeting as we demonstrated in previous
research [94]. We have previously reported on renal clearable AuNCs integrated with 64Cu
(64Cu-AuNCs) which showed minimal nonspecific organ retention, largely reduced mononuclear
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phagocytosis system accumulation, and precise detection of cancer biological targets in both
primary tumor and distant metastasis using positron emission tomography (PET) [94].
Meanwhile, their size was close to that of monoclonal antibodies, which are used with increasing
success against many tumors [143]. The first-in-human trial is now ongoing to determine the
safety of small-size gold nanoparticles (13 nm in diameter) labeled with spherical nuclei acid in
treating patients with recurrent glioblastoma or gliosarcoma (ClinicalTrials.gov Identifier:
NCT03020017).
We selected the brainstem as the targeted brain location because our long-term goal is to use
FUSIN for the treatment of diffuse intrinsic pontine glioma (DIPG). DIPG, a high-grade glioma
that spreads throughout the brainstem, has replaced leukemia as the leading cause of cancer
death among children. It has a median survival of less than one year, a dismal prognosis that has
remained unchanged over the past 40 years [144]. There are two main reasons why treatment of
DIPG is challenging. First, in contrast to other high-grade gliomas (e.g., glioblastoma), which
often have a compromised BBB, the BBB in DIPG is frequently intact, as suggested by the lack
of contrast enhancement on contrast-enhanced magnetic resonance imaging [77]. Second, the
brainstem controls basic life functions, such as breathing, hearing, taste, balance, and
communication between different parts of the brain. The critical anatomic location of the
brainstem precludes surgical intervention and limits the use of other invasive therapeutic
techniques. Therefore, techniques that can noninvasively circumvent the BBB can have a
significant clinical impact in treating DIPG. FUSIN has the potential to improve DIPG treatment
by bypassing the BBB and addressing the critical need, shared by many pediatric brain diseases,
for noninvasive and targeted delivery of therapeutics to the diseased brain site, while minimizing
injury to healthy regions of the developing brain and other organs. In addition, the brainstem is
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also unique in that it is directly connected with the nasal cavity through the trigeminal nerve. Our
previous studies showed that FUSIN delivered different agents to the caudate putamen [70,96].
This study explored the potential to expand the application of FUSIN for drug delivery to the
brainstem.

4.3 Materials and methods
Animals
All animal procedures were reviewed and approved by the Institutional Animal Care and Use
Committee of Washington University in St. Louis, in accordance with the National Institutes of
Health Guidelines for animal research. C57BL/6 female mice (6–8 weeks, ~25 g body weight)
were purchased from Charles River Laboratory (Wilmington, MA, USA). The animals were
housed in a room maintained at 72oF and 55% relative humidity, with a 12-h/12-h light/dark
cycle, and provided access to standard laboratory chow and tap water. Mice were divided into
multiple groups (Table 4.1).
Table 4. 1: Summary of all study groups.

Study
Biodistribution of IN vs.
IV administered AuNCs

Groups
64

Cu-AuNCs + IN (n=4)

1

PET and gamma counting
64

Cu-AuNCs + IV (n=4)

64

Feasibility of FUSIN for
the delivery of AuNCs

Analysis

2

Cu-AuNCs
(n=5)

+

FUSIN
Autoradiography

64

Cu-AuNCs + IN (n= 3)

3

TR-AuNCs + FUSIN (n=3)

58

Fluorescence imaging

Non-treated control (n=3)

4
Short-term safety of
FUSIN

TR-AuNCs + IN (n=3); Fluorescence imaging of
Sacrificed1 h post IN
the nasal tissue and
trigeminal nerve
TR-AuNCs + IN (n=3);
Sacrificed 24 h post IN
Non-treated control (n=3)

5
TR-AuNCs + FUSIN (n=3)

Histological staining of
the
nasal
tissue,
trigeminal nerve, and
brain

Synthesis and characterization of AuNCs
64

Cu-AuNCs were synthesized as described previously [28]. In a typical reaction, water (2.0

mL), HAuCl4 (10 mM, 376 µL), and 64CuCl2 (74 MBq) were mixed in a glass vial, followed by
the dropwise addition of mPEG-lipoamide (MW = 750 Da, 10 mM, 400 µL). After the mixture
was stirred overnight, sodium borohydride (40 mM, 400 µL) was added and stirred rapidly for 2
h. The 64Cu-AuNCs were collected by first filtering the solution through an Amicon 50K
centrifuge filter and subsequently purifying the solution with an Amicon 10K centrifuge filter.
Radiochemical purity was determined using silica impregnated iTLC paper with a mobile phase
of 1:1 methanol: 10% ammonium acetate. The synthesis and purification procedures for the
Texas red-labeled AuNCs (TR-AuNCs) was similar to the above procedures with additional
addition of 5% (molar fraction) lipoamido-dPEG12-Texas red in 10 µL dimethyl sulfoxide to the
solution after the addition of mPEG-lipoamide to HAuCl4 and stirred in darkness. Same as that
reported in our previous publication [28], the prepared AuNCs had a homogenous distribution as
characterized by transmission electron microscopy (Tecnai G2 Spirit Transmission Electron
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Microscope, Hillsboro, OR). Dynamic light scattering (Zetasizer Nano ZS, Malvern Instruments,
Malvern, UK) measurements found their hydrodynamic sizes were 5.60±1.50 nm.
IN administration
The IN administration procedure was the same as described before [5]. Mice were placed supine
on a curved holder under 1.5% isoflurane anesthetization. Drops (3 µl for each drop) of AuNCs
suspended in saline solution was administered to the mouse nose by alternating between the left
or right nostril every 2 mins. Those drops were placed at the opening of the nostril, allowing the
animal to snort each drop into the nasal cavity. A total of 8 drops (24 µL) were administered to
each mouse. The administered AuNC dose was ~45 mg/kg mouse body weight.
Biodistribution evaluation of IN administration
One group of mice (n=4) were administered with 64Cu-AuNCs (3.7 MBq/mouse) through IN
administration. The other group of mice (n = 4) were intravenously injected with 64Cu-AuNCs
(3.7 MBq/mouse) through the tail vein. In vivo PET/CT scans were performed using the Inveon
PET/CT system (Siemens, Malvern, PA) at 1 h post IN administration or IV injection. The PET
images were corrected for attenuation, scatter, and camera dead time, and were co-registered
with the CT images. The PET images were reconstructed with the maximum a posteriori (MAP)
algorithm using Inveon software. After PET imaging, blood was collected from the mouse heart,
and each mouse was transcardially perfused with phosphate-buffered saline followed by 4%
paraformaldehyde. All the major organs were harvested after perfusion. Then, the collected
blood and organs were placed in tested tubes, weighed, and counted using a Beckman 8000
gamma counter (Beckman, Fullerton, CA). The count rate (counts per minute, CPM) for each
sample was corrected by automatic background subtraction and decay correction (compensate
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for the decay of 64Cu radioactivity over time). The corrected CPM from each tissue sample was
then normalized to both the mass of the tissue sample (in grams, g) and the injected dose (ID) for
the quantification of 64Cu-AuNCs biodistribution in terms of %ID/g. The above study was
performed by trained technicians at the Pre-clinical PET/CT Imaging Facility at Washington
University in St. Louis.
FUSIN treatment
Two FUS systems, one for the delivery of non-radiolabeled AuNCs and the other for the delivery
of 64Cu-AuNCs, were used in this study. The second system was needed as it was placed in a
room approved for the use of radioactive materials and dedicated for the delivery of radioactive
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Cu-AuNCs. Both systems were carefully calibrated using a needle hydrophone (HGL-0200,

Onda Corporation, Sunnyvale, CA, USA) to ensure consistent output from these two systems.
The first FUS system (VIFU 2000; Alpinion US Inc., Bothell, WA, USA) consisted of a FUS
transducer with a center frequency of 1.5 MHz, a focal depth of 60 mm, an aperture of 60 mm,
and a circular central opening of 38 mm. The transducer was mounted to a 3D stage for precise
positioning (Velmex, Lachine, QC, Canada). The transducer was attached to a water balloon
filled with degassed water to provide acoustic coupling. The water balloon was immersed in a
degassed water container, the bottom of which featured a window sealed with an acoustically
and optically transparent membrane (Tegaderm; 3M, St. Paul, MN, USA). A B-mode imaging
probe (L8-17, working frequency 8-17 MHz, center frequency 12 MHz, Alpinion, Seoul, Korea)
was inserted into the FUS transducer center opening and aligned with the FUS focal plane.
Treatment planning was executed with the assistance of a grid [33]. The grid was positioned in
the water container on top of the mouse head with the crossing point in alignment with the
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lambda, an anatomic landmark on the skull that is visible through the mouse skin on the head.
The B-mode imaging probe was scanned through the grid to form a 3D image of the grid using a
customized Matlab (R2016b; Mathworks inc., Natick, MA, USA) program. The crossing point of
the grid was then identified and used as the reference point to align the FUS focus at one selected
point on the left side of the brainstem based on its stereotactic location relative to the lambda (0
mm frontal and 1.5 mm to the left). The depth of the FUS focus was adjusted to be 4.0 mm from
the skull by measuring the distance from the skull on the B-mode images.
The second system used a FUS transducer (University of Texas Southwestern, Dallas, TX, USA)
with an aperture of 75 mm and a radius of curvature of 60 mm. The transducer was impedancematched to operate at 1.5 MHz, the same as the first system. The transducer was driven by an
arbitrary waveform generator (Agilent 33500B; Agilent Technologies, Loveland, CO, USA)
connected to a power amplifier (1020L; E&I, Rochester, NY, USA). The function generator was
controlled by a customized MATLAB program. A stereotaxic apparatus (Kopf, Tujunga, CA,
USA) was used for targeting the brainstem [34]. A pointer was fixed on the stereotactic frame
and well characterized to indicate the focus of the transducer. After aligning the tip of the pointer
with the lambda, the pointer was then replaced by the FUS transducer, and the transducer was
moved to target the brainstem based on the stereotactic location of the brainstem.
The pressure amplitudes and beam profiles of the two FUS transducers were calibrated using a
needle hydrophone in a degassed water tank before the experiment. The reported pressure
amplitudes were corrected for 18% mouse skull attenuation [33]. The axial and lateral full-widthat-half-maximum (FWHM) focal regions of the FUS transducer in the first system were 6.04 mm
and 0.62 mm, respectively. The FWHM dimensions of the FUS transducer in the second system
were 8.62 mm and 1.00 mm, respectively.
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For the FUSIN treatment using both systems, AuNCs were administered to the mice before
placing the mice prone on a heating pad with their heads immobilized by the stereotaxic frame.
The fur on the mouse head was removed while the skull and the scalp remained intact. The water
container was placed on the mouse head and coupled with degassed ultrasound gel. The FUS
transducer was then adjusted to target the brainstem, using the method described above.
Microbubbles comprised of a liquid shell made of 90 mol% 1,2-distearoyl-sn-glycero-3phosphocholine (DSPC, Avanti Polar Lipids, Alabaster, AL) and 10 mol% 1,2-distearoyl-snglycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (DSPE-PEG2000,
Avanti Polar Lipids, Alabaster, AL) and a perfluorobutane gas core (FluoroMed, Round Rock,
TX) were manufactured in-house according to a previously described protocol [22]. Sizeselected microbubbles with a median diameter of 4–5 μm were isolated from a polydispersed
microbubble distribution using a differential centrifugation method [22] and diluted using sterile
saline to a final concentration of approximately 8×108 number of microbubbles per mL. The
diluted microbubbles (volume = 30 μL) were administered through a bolus injection via the tail
vein. Immediately (~9 s) following microbubbles injection, FUS treatment was performed using
the following parameters: peak-negative pressure = 0.56 MPa, pulse length = 6.7 ms, pulse
repetition frequency = 5 Hz, and duration = 1 min.
Spatial distribution of the delivered 64Cu-AuNCs in the brain
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Cu-AuNCs were delivered to mice in the IN-only group (n=3) and FUSIN group (n=5). All the

mice were transcardially perfused at 1 h post-IN administration. The excised brains were sliced
into 2-mm coronal sections using a brain matrix (RBM-2000C; ASI Instruments, Inc., Warren,
MI, USA). The slices were placed on a phosphor-imaging plate for overnight exposure. The
radioactivity of the brain slices was detected by autoradiography [35,36] using a Storm 840
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Phosphorimager (GE, Marlborough, MA). The FUS-treated brain slices were selected and
quantified using ImageJ (NIH, Bethesda, MD, USA) by calculating the total radioactivity of
those slices. The radioactivity of the corresponding slices acquired from mice in the IN only
group was also quantified for comparison.
Spatial distribution of the delivered TR-AuNCs in the brain
TR-AuNCs were intranasally administered to mice (n = 3) and FUS treatment was targeted at the
left side of the brainstem with the contralateral right side of the brainstem used as the control for
IN administration only. The animals were transcardially perfused at 1 h post-IN administration.
The mouse brains were harvested and fixed overnight in paraformaldehyde followed by
cryoprotection with sucrose. The brains were cut into horizontal sections (the thickness of each
section was 60 μm) and imaged using a fluorescence microscope (Axiovert S100; Zeiss,
Oberkochen, Germany). For each mouse, a customized Matlab program was used to quantify the
fluorescence intensity using 12 sequential brain slices acquired at the targeted brain location
[37]. Circles with a 2-mm diameter were selected by the Matlab program on the left and right
sides of the brainstem as the regions of interests (ROIs). Another circle was drawn outside of the
brain for the calculation of the background image intensity. The sum of the pixel intensities
within each ROI was normalized by the mean background image intensity of each slice. The
average of the normalized intensities of the 12 sequential brain slices was calculated for the leftand right-side ROIs.
TR-AuNCs distribution in the nose and nerve
TR-AuNCs were intranasally delivered to six mice, three of them were sacrificed at 1 h (n=3),
and the remaining three were sacrificed at 24 h (n=3). The nasal tissue and trigeminal nerves
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were carefully extracted from these two groups of mice. They were examined using a
fluorescence imaging system (Bruker Corporation, Billerica, MA). Tissue from mice (n=3)
without TR-AuNCs administration were used as the control. The exposure time for the
fluorescence imaging was kept the same for all samples.
Histological analysis
Histologic examinations of the mouse whole brain, nose, and trigeminal nerve were performed to
verify the short-term (1 h after treatment) safety of FUSIN. The harvested mouse brains were
fixed in 4% paraformaldehyde and embedded in paraffin. The brains were sectioned horizontally
into 6 µm thick slices at 10 separate levels, with 180 µm intervals between two adjacent levels.
At each level, four sections were acquired and stained with Hematoxylin and eosin (H&E). The
mouse noses were immersed overnight in a decalcifying solution before paraffin embedding. The
nasal tissue was also sectioned into 6 µm thicknesses and then stained with H&E. The trigeminal
nerves were fixed overnight in paraformaldehyde followed by cryoprotection with sucrose, then
sectioned into 10 µm sections and stained with Luxol fast blue-cresyl violet (LFB-CV).
Histological evaluation was performed single-blinded, by a trained observer without knowledge
of the location and parameters of sonication.
Statistical analysis
Statistical analysis was performed using GraphPad Prism (Version 5.01, La Jolla, CA, USA).
Group variation was described as mean ± standard deviation. Differences between two groups
were determined using the unpaired two-tailed Student’s t-test. A p-value of 0.05 was considered
to represent a significant difference.
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4.4 Results
Figure 4.1 compares the whole-body biodistribution of

64

Cu-AuNCs at 1 h after IN

administration and IV injection. The PET/CT image of mouse administrated with
via IV route (Fig. 4.1A) shows multiple organs distribution of

64

64

Cu-AuNCs

Cu-AuNCs in contrast to that

observed via IN injection, which was further confirmed by the biodistribution study shown in
Figure 4.1B. Gamma counting found the 64Cu-AuNCs accumulation was significantly higher in
the IV group (n=4) than in the IN group (n=4) in the blood (P<0.001; the ratio of the mean
concentrations: IV/IN = 73), lung (P<0.001; IV/IN = 59), liver (P<0.001; IV/IN = 12), spleen
(P<0.05; IV/IN = 15), kidney (P<0.001; IV/IN = 11), and heart (P<0.001; IV/IN = 79). No
statistically significant difference was found in muscle (P>0.05; IV/IN = 40;), fat (P>0.05;
IV/IN = 37), bone (P>0.05; IV/IN = 43), marrow (P>0.05; IV/IN = 18), pancreas (P>0.05; IV/IN
= 15), brain (P>0.05; IV/IN = 1), and intestine (P>0.05; IV/IN = 1). Significant higher
radioactivity by IN administration was only observed in the stomach (P<0.001; IN/IV=8).
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Figure 4. 1: (A) Representative in vivo PET/CT images of mouse whole body coronal view at 1 h after IN
administration (left) or IV injection of 64Cu-AuNCs (right). (B) Biodistribution of 64Cu-AuNCs measured
at 1 h post-IN administration (n=4) or IV injection (n=4) in different organs as quantified by gamma
counting. The IN group showed less radioactivity in most organs than that of the IV group with
significantly higher 64Cu-AuNCs accumulation observed only in the stomach.
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Figures 4.2A and 4.2C are representative autoradiographs of ex vivo coronal brain slices from
mice treated with IN only and FUSIN, respectively. The corresponding photographs of the slices
are presented in Figs. 4.2B and 4.2D to show the anatomical structures of the brain. For the
FUSIN-treated mice, FUS was targeted at the left side of the brainstem. Locally enhanced
accumulation of

64

Cu-AuNCs was observed at the FUS-targeted location (Fig. 4.2C). The

elongated distribution of the radioactivity in the coronal slice was expected as the FWHM
dimension of the FUS transducer in the coronal view was 8.62 mm. Quantification of the
radioactivity found the radioactivity of

64

Cu-AuNCs delivered by FUSIN was 2.72±0.79 fold

higher than that by IN (Fig. 4.2E).

Figure 4. 2: Representative autoradiographs and corresponding photographs of 64Cu-AuNCs in coronal
brain slices from mice in the (A, B) IN administration group, and (C, D) FUSIN treatment group,
respectively. The arrow in C points to the location where the FUS was targeted for the FUSIN treatment.
(E) Quantification of the radioactivity shows statistically significant higher radioactivity was observed in
mice treated with FUSIN than IN only ( ***: P < 0.001).
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Fluorescence imaging of ex vivo brain slices from mice administered with TR-AuNCs further
confirmed that FUSIN achieved local accumulation of TR-AuNCs at the FUS-targeted location.
Figure 4.3 shows representative fluorescence images of the FUSIN-treated side of the brainstem
(Fig. 4.3B) and contralateral non-treated control side (Fig. 4.3A) from the same brain slice.
Strong fluorescence signals were observed in the FUS-treated side of the brainstem with minimal
signals observed in the non-treated side. Several blood vessels pointed out by arrows in Fig. 4.3B
are highlighted by TR-AuNCs in the perivascular space. Enhanced delivery of TR-AuNCs to the
FUS-treated brainstem was consistently found within this group of mice. Quantifications of the
fluorescence images revealed a 2.32±1.12-fold enhancement in the fluorescence intensity of TRAuNCs delivered by FUSIN, compared with IN only.

Figure 4. 3: Representative fluorescence images of a brain slice obtained from a mouse administered
with TR-AuNCs followed by FUS treatment on one side of the brainstem (B) and no FUS treatment on the
contralateral side of the brainstem (A). The blood vessels are clearly highlighted by the TR-AuNCs in the
FUSIN-treated side (arrows). (C) Quantification of the fluorescence intensities found significantly higher
fluorescence intensity was observed with FUSIN than IN (*:P < 0.05, n=3).

Figure 4.4 displays photographs and corresponding fluorescence images of the mouse nose tissue
and trigeminal nerve harvested at 1 h (Figs. 4.4C and 4.4D) and 24 h (Figs. 4.4E and 4.4F) after
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IN delivery of TR-AuNCs. Mice without TR-AuNCs delivery served as the control (Figs. 4.4A
and 4.4B). The nose and trigeminal nerve extracted at 1 h after IN administration exhibited
stronger fluorescence signals than those of the control group, confirming that the trigeminal
nerve serves as a pathway for IN delivery. At 24 h post IN administration, the intensity of the
fluorescence signals was close to the control, indicating TR-AuNCs can be cleared from the nose
and trigeminal nerve.

Figure 4. 4: Photographs and corresponding fluorescence images display the distributions of TR-AuNCs
in the nose and trigeminal nerve of mice in the control group (A, B), mice sacrificed 1 h after TR-AuNCs
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IN administration (C, D), and mice sacrificed 24 h after TR-AuNCs IN administration (E, F). The blue
color in the nose tissue in (C) was the color of the TR dye.

No hemorrhage was observed in the FUSIN-treated brain (Fig. 4.5B) compared to the control
without FUS treatment (Fig. 4.5A). Nasal sections showed no damage to nasal tissue in either the
FUSIN TR-AuNCs group (Fig. 4.5D) or the non-treated control group (Fig. 4.5C). The LFB-CV
stained trigeminal nerve sections from both the non-treated control group (Fig. 4.5E) and FUSIN
treated group (Fig. 4.5F) did not show histological-level changes in the nerve.
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Figure 4. 5: Histological examinations by H&E staining of (A) the non-sonicated and (B) the
contralateral FUS-sonicated brainstem reveal no hemorrhage associated with the FUS treatment. H&E
staining of the nasal sections from (C) the control mice without agent delivery and (D) the mice with IN
administered TR-AuNCs found no damage to the nasal tissue by IN administration. The LFB-CV staining
of trigeminal nerves from (E) the non-treated control mice and (F) the mice with IN administration of TRAuNCs shows IN administration of AuNCs did not cause damage to the nerve tissue.
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4.5 Discussion
Our study using in vivo microPET/CT imaging and ex vivo gamma counting confirmed that IN
administration of

64

Cu-AuNCs contributed to minimal systematic exposure (Fig. 4.1).

Quantification of the radioactivity in major organs collected from mice injected with

64

Cu-

AuNCs via IV showed more than 10-fold uptake in blood, lung, liver, spleen, kidney, and heart
than those via IN administration. Significant higher radioactivity by IN administration was only
observed in the stomach. These findings suggest that

64

Cu-AuNCs are likely to be removed by

mucus to the nasopharynx and accumulated in stomach and intestine [145], which allows the
nanoclusters to be excreted from the animal through feces, leading to minimized systemic
toxicity of the AuNCs. Previous studies have found consistent results that minimized systemic
exposure was associated with IN delivery of larger nanoparticles–micelles (~600 nm) [146] .
Here we showed that the small-size AuNCs share the same advantage in minimizing systemic
exposure as those larger-size nanoparticles.
In order to achieve effective drug delivery via the nasal route to the brain, innovative designs of
nanoparticles were proposed with promising results [70,96]. However, IN brain drug delivery is
still limited by its inefficient and non-localized delivery, which was verified by our data (Figs.
4.2A and 4.3A). Integrating IN administration and FUS, we showed locally enhanced delivery of
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Cu-AuNCs and TR-AuNCs to the FUS-targeted brainstem area (Figs. 4.2C and 4.3B). The

radioactivity of

64

Cu-AuNCs delivered by FUSIN and the fluorescence intensity of TR-AuNCs

delivered by FUSIN were both more than two-fold higher than that of IN only (Figs. 4.2E and
4.3C). Previous studies on IN brain drug delivery concentrated on enhancing the agent
absorption across the nasal epithelium to improve the IN delivery efficiency to the brain [15, 34,
73

35]. This study showed that IN delivery efficiency can be improved by FUSIN, which enhanced
the accumulation of IN administered agents by inducing microbubble cavitation at the desired
brain location. Meanwhile, the capability of FUSIN in localized nanoparticle delivery makes it
possible to achieve therapeutic drug level only within the targeted site while keeping nontargeted sites at sub-therapeutic level, thus minimizing any potential side effects to healthy
regions of the brain. It is noted that the quantification of radioactivity and fluorescence intensity
was an indirect estimation of the AuNC delivery efficiency. Future study is needed to provide
direct quantification of the AuNC delivery efficiency in terms of %ID or %ID/g using methods
such as inductively coupled plasma mass spectrometry (ICP-MS) to directly measure the Au
concentrations.
Previous studies have shown that FUSIN noninvasively enhanced the localized delivery of
fluorescently labeled dextran (40 kDa) and BDNF (27 kDa) to the caudate putamen of mouse
brains [70,96]. These previous findings, combined with our current results, suggest that FUSIN
is a promising platform technology for delivering different types of agents to different brain
locations. Future studies are needed to compare the delivery efficiencies of different agents to the
same targeted brain location to evaluate the dependency of the FUSIN delivery efficiency on the
types of the therapeutic agents, as well as to compare the delivery efficiency of the same agent to
different locations to assess the location-dependency of FUSIN.
It is worthwhile to point out that FUSIN relies on the same mechanical interactions among FUS,
microbubbles, and microvessels as the conventional FUS-induced BBB opening technique.
AuNCs that entered the blood circulation through IN-administration may be delivered from the
blood circulation to the brain parenchyma through the BBB. However, the level of AuNCs in the
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blood after IN administration was minimal, with a concentration 73-fold lower than that after IV
administration (Fig. 4.1B). This finding is consistent with previous studies showing that IN
delivered agents were directly transported from the nose to the brain through the olfactory nerve
and trigeminal nerve pathways with minimal amounts entering the blood circulation
[60,138,146,147]. This finding suggests that the enhanced delivery observed in the brain by
FUSIN was mainly due to the contribution of the nose-to-brain pathway instead of the blood-tobrain pathway.
Extensive research has demonstrated the safety of IN administration [148], which justifies IN
brain drug delivery studies in animals and early-phase clinical trials. The IN administration
method that we used in this study followed a standard protocol for mice that have been used by
several other groups [65,149]. To verify the safety of IN administration, we performed H&E
staining of the nasal tissue obtained from mice treated by IN administration of TR-AuNCs and
found no changes in the nasal tissue compared with the control group (Figs. 4.5C and 4.5D).
The enhanced fluorescence signals observed in the fluorescence images of the trigeminal nerve
at 1 h confirmed that the trigeminal nerve is a pathway for IN delivery to the brainstem. The
fluorescence image acquired at 24 h post IN administration of TR-AuNCs (Fig. 4.4F) showed a
fluorescence intensity close to that of the control (Fig. 4.4B), suggesting clearance of the
nanoparticles from the nerve. No change was observed by comparison of the stained trigeminal
nerves from mice treated by FUSIN and those from the non-treated control group (Figs. 4.5E and
4.5F).
Since the brainstem coordinates motor control signals to the body and controls life supporting
autonomic functions of the peripheral nervous system, the parameters of FUS were carefully
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chosen in reference to previous FUS-induced BBB opening studies to avoid hemorrhage or
neuron damage [79,100]. As expected, these parameters did not cause any vascular or tissue
damage at the FUS targeted brainstem region (Fig. 4.5B). Although not the focus of this study,
we closely observed the mice behavior until the animals fully recovered from anesthesia. All
treated mice recovered from anesthesia within 15 min after the FUS treatment. After recovery,
no gross behavior change was observed in drinking, eating, walking, hanging, jumping, or
grooming.
There are several major limitations of this study. First, the treatment timeline and FUS
parameters were not optimized. The FUS treatment parameters were selected in reference to
previous studies of the FUS-induced BBB opening technique. Future studies must refine these
parameters to improve the delivery efficiency of FUSIN. Meanwhile, ex vivo autoradiography
and fluorescence imaging were used to assess the AuNCs distribution in the mouse brain. Future
studies are needed to determine the pharmacokinetics of the AuNCs using in vivo PET/CT
imaging in order to reveal the spatiotemporal kinetics of AuNCs delivered by FUSIN. The safety
evaluation of FUSIN was performed after a single treatment within a short-term period (1 h after
treatment). Future studies are needed to evaluate the long-term safety of FUSIN, especially after
repeated treatments. Moreover, we used AuNCs with only one size in this study. Future studies
will optimize the design of the AuNCs, such as size and surface charge, to optimize the FUSIN
delivery outcome. Last but not least, we showed minimized exposure of the AuNCs to major
organs, but we did not systemically evaluate the toxicity of the AuNCs. Future studies are
needed to systemically evaluate the safety of AuNCs, including hepatotoxicity, hematological
toxicity, and inflammatory response to fully demonstrate the advantage of FUSIN in minimizing
nanoparticle toxicity.
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4.6. Conclusion
Brain drug delivery is not only challenged by the limited delivery efficiency due to the existence
of the BBB but also the need to reduce systemic toxicity. This study showed the advantage of IN
administration of AuNCs in minimizing systemic exposure compared with systemic injection. It
found that FUSIN achieved localized and enhanced delivery of AuNCs compared with IN brain
drug delivery. A short-term safety evaluation of FUSIN-treated mice did not find histologicallevel tissue damage to the nose, trigeminal nerve, and brain. These findings suggest that FUSIN
is a promising technique for noninvasive, spatially targeted, and safe delivery of nanoparticles to
the brain with minimal systemic exposure.
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Chapter 5: Comparison of FUSIN and FUSBBBD in the delivery of gold nanoclusters to the
brainstem
5.1 Abstract
One critical obstacle to the effective treatment of many brain diseases is the blood-brain barrier
(BBB). Focused ultrasound-induced BBB disruption (FUS-BBBD) has been established as a
promising technique for the trans-BBB delivery of agents in the systemic circulation. Focused
ultrasound-mediated intranasal delivery (FUSIN) is a newly reported technique for brain drug
delivery by integrating FUS and microbubbles to enhance the accumulation of intranasally
administered drugs at the FUS-targeted brain location. The objective of this study was to
compare the delivery efficiency, systemic exposure, and delivery routes of FUSIN and FUSBBBD for the delivery of nanoparticles to the targeted brain location. Texas red-labeled gold
nanoclusters (TR-AuNCs) were used as the model agent, and the brainstem was selected as the
targeted brain location. Mice in the FUSIN group were administered with TR-AuNCs through
the nose and treated by FUS after injecting microbubbles through the tail vein. FUS was targeted
at the brainstem. Mice in the FUS-BBBD group were injected with the same amount of TRAuNCs combined with microbubbles through the tail vein followed by the same FUS treatment
as in FUSIN. All the mice were sacrificed at 30 min after the FUS treatment. The distribution of
TR-AuNCs to the ex vivo mouse brain and other major organs, as well as the blood, nasal tissue,
and trigeminal nerve, were imaged using fluorescence imaging and quantified using inductively
coupled plasma-mass spectrometry (ICP-MS) analysis of Au concentration. FUSIN achieved 25fold higher delivery of the TR-AuNCs to the brainstem than that of the FUS-BBBD. FUSIN was
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associated with one order of magnitude lower systemic exposure than that of FUS-BBBD in
heart, lung, spleen, kidney, and liver. The amount of Au in the nasal tissue and trigeminal nerve
of mice in the FUSIN group was 290-fold and 72-fold higher than those of the FUS-BBBD
group, respectively; while the amount of Au in the blood of mice in the FUS-BBBD group was
109-fold higher than that of the FUSIN group. This study found that FUSIN achieved
significantly higher delivery of TR-AuNCs to the brainstem than FUS-BBBD with minimal
systemic exposure. It also verified that FUSIN delivered the TR-AuNCs through the nose-tobrain route, while FUS-BBBD utilized the blood-to-brain route. In summary, FUSIN is a
promising technique for noninvasive, efficient, and localized delivery of nanoparticles to the
brainstem with minimal systemic exposure.

5.2 Introduction
Disorders in the brain affect millions of people worldwide. One critical obstacle to the effective
treatment of many brain diseases is the blood-brain barrier (BBB). The BBB regulates the traffic
of most molecules between the blood circulation and the brain. Unfortunately, it also limits
systemically administered imaging or therapeutic agents from reaching the brain in sufficient
concentrations [134]. Some brain diseases, such as glioblastoma, have compromised BBB with
increased permeability compared to the intact BBB; however, the permeability of the BBB is
often heterogeneous, and high interstitial pressure in the brain further limits the delivery of
systemically administered agents [150]. In some other brain malignancies, such as diffuse
intrinsic pontine glioma (DIPG), the BBB is often intact as suggested by non-enhancing
magnetic resonance imaging (MRI) images after MRI contrast agent administration [151]. Our
long-term goal is to develop brain drug delivery techniques that can circumvent the BBB for the
treatment of DIPG, a high-grade glioma that spreads throughout the brainstem. DIPG has
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replaced leukemia as the leading cause of cancer death among children. It has a median survival
of less than one year, a dismal prognosis that has remained unchanged over the past 40 years
[144]. The brainstem controls basic life functions, such as breathing, hearing, taste, balance, and
communication between different parts of the brain. The critical anatomic location of the
brainstem precludes surgical intervention and limits the use of invasive therapeutic techniques.
Treatment of brain diseases also is challenging because many therapeutic agents that have
potentially beneficial effects on the brain have adverse side effects in other organs. Therefore,
techniques that can noninvasively circumvent the BBB with minimized systemic exposure can
have a significant clinical impact in the treatment of DIPG as well as many other brain diseases.
Transcranial focused ultrasound (FUS) in combination with microbubbles has been established
as a promising technique for noninvasive, localized, and reversible BBB disruption (FUSBBBD). The strategy of combining FUS with microbubbles for drug delivery across the BBB
was first reported more than a decade ago [35]. Subsequent studies in rodent and non-human
primates have confirmed that FUS can induce temporary BBB opening without observable tissue
damage or functional deficits even after repeated treatment [78,152]. FUS-BBBD has been used
to deliver a wide range of therapeutic agents across the BBB to the brain, including small
molecule drugs [153], recombinant proteins [48–50], viruses [51,52], and even cells [154,155].
Early phase clinical trials on evaluating the feasibility and safety of FUS-BBBD in patients with
glioblastoma [156] and Alzheimer’s disease [157] are currently on-going.
Nanoparticles offer exciting opportunities for brain disease treatment but the effective
nanoparticle delivery to the brain is the major challenge [158]. There has been a growing interest
in using FUS for the trans-BBB delivery of nanoparticles, which takes advantage of the
noninvasive and localized BBB disruption capability of FUS and the unique characteristics of
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nanoparticles as multicomponent constructs containing imaging, targeting, and therapeutic
entities. It has been reported that FUS-BBBD improved the delivery of various systemically
injected nanoparticles, such as chemotherapeutic drug-loaded liposomes [159], biodegradable
polymeric nanoparticles [86], magnetic nanoparticles [82], gold nanoparticles [87], and lowdensity lipoprotein nanoparticles reconstituted with docosahexaenoic acid (DHA) [83]. Recently,
ultrasmall renal clearable nanoclusters have drawn significant attention for biomedical
applications due to their size-promoted clearance and low mononuclear phagocytic system
retention after systematic injection [89–93], and accurate tumor targeting as we demonstrated in
previous research [94]. However, FUS-BBBD requires the nanoparticles to be injected
intravenously (IV) into the blood circulation, and IV injection is associated with systemic
exposure of the injected agents.
IN delivery provides an alternative route for drug administration because it is a painless, simple,
and noninvasive approach that allows direct agent delivery from nose to the brain, eliminating
the need for systemic delivery and thereby minimizing associated side effects. IN administration
has been used for brain delivery of a wide-range of therapeutics (e.g., peptides [160], proteins
[138], gene vectors [161], nanoparticles [162], and stem cells [163]) not only in animal studies
but also in humans [60,164]. However, IN brain drug delivery is inefficient to reach the
therapeutic level and not diseased-site targeted, which significantly limits its application in
translational research [68,165]. FUS-mediated intranasal delivery (FUSIN) is a new brain drug
delivery technique that harvests the unique advantages of IN administration for direct nose-tobrain drug administration and FUS in combination with microbubbles for targeted and enhanced
delivery to the brain. FUSIN was first reported in 2014 and showed improved delivery of
dextrans and a protein drug (brain-derived neurotrophic factor) at the FUS-targeted caudate
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putamen of mouse brains [70,96]. No study has been performed to compare FUSIN with the
more established FUS-BBBD technique.
The objective of this study was to compare the delivery efficiency, systemic exposure, and
delivery routes of FUSIN and FUS-BBBD for the delivery of Texas red-labeled gold
nanoclusters (TR-AuNCs) to the brainstem. We also performed histological analysis to assess the
safety of FUSIN at the histological level.

5.3 Materials and methods
Animals
All animal procedures were reviewed and approved by the Institutional Animal Care and Use
Committee of Washington University in St. Louis, in accordance with the National Institutes of
Health Guidelines for animal research. C57BL/6 female mice (6–8 weeks, ~25 g body weight)
were purchased from Charles River Laboratory (Wilmington, MA, USA). The animals were
housed in a room maintained at 72oF and 55% relative humidity, with a 12-h/12-h light/dark
cycle, and provided access to standard laboratory chow and tap water. Mice were divided into
four groups (n=3 for each group): (1) FUSIN: IN administration of TR-AuNCs followed by FUS
treatment; (2) FUS-BBBD: IV injection of TR-AuNCs followed by FUS treatment; (3) IN: IN
administration of TR-AuNCs; and (4) IV: IV injection of TR-AuNCs. An additional six mice
were divided into two groups, FUSIN and FUS-BBBD, for histological examination of the
mouse brain, nose, and trigeminal nerve.
Synthesis and characterization TR-labeled AuNCs
TR-AuNCs were synthesized as described previously [93]. In a typical reaction, water (2.0 mL),
HAuCl4 (10 mM, 376 µL) were mixed in a glass vial, followed by the dropwise addition of
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mPEG-lipoamide (MW = 750 Da, 10 mM, 400 µL). After the mixture was stirred overnight,
sodium borohydride (40 mM, 400 µL) and 5% (molar ratio) lipoamido-dPEG12-Texas red in 10
µL dimethyl sulfoxide. After the mixture was stirred overnight in darkness, sodium borohydride
(40 mM, 400 µL) were added and stirred rapidly for 2 h in darkness. TR-AuNCs were collected
by first filtering the solution through an Amicon 50K centrifuge filter and subsequently purifying
the solution with an Amicon 10K centrifuge filter. The prepared AuNCs had a homogenous
distribution as characterized by transmission electron microscopy (Tecnai G2 Spirit
Transmission Electron Microscope, Hillsboro, OR) with one representative image shown in
Figure. 5.1A. Dynamic light scattering (Zetasizer Nano ZS, Malvern Instruments, Malvern, UK)
measurements found their hydrodynamic sizes were 5.60±0.50 nm.
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Figure 5. 1: A) Transmission electron microscopy image of the TR-AuNCs. B) Experimental setup. An
ultrasound imaging-guided FUS system was used for the FUS treatment. A grid was used for assisting
FUS targeting of specific brain location. C) Experimental timeline for FUSIN and FUS-BBBD. For
FUSIN, TR-AuNCs were administered to the mice through the nose followed by microbubble injection.
For FUS-BBBD, TR-AuNCs were co-injected with microbubbles. The FUS treatment parameters and
post-treatment tissue processing procedures were the same for FUSIN and FUS-BBBD.

IN administration
The IN administration procedure was the same as described before [70]. Mice were placed
supine on a curved holder under 1.5% isoflurane anesthetization. Drops (3 µl for each drop) of
TR-AuNCs suspended in saline solution were administered to the mouse nose by alternating
between the left or right nostril every 2 mins. Those drops were placed at the opening of the
nostril, allowing the animal to snort each drop into the nasal cavity. A total of 8 drops (24 µL)
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were administered to each mouse. The administered AuNCs dose was ~45 mg/kg mouse body
weight.
FUS treatment
An ultrasound imaging-guided FUS system (VIFU 2000; Alpinion US Inc., Bothell, WA, USA)
consisted of a FUS transducer with a center frequency of 1.5 MHz, a focal depth of 60 mm, an
aperture of 60 mm, and a circular central opening of 38 mm was used in this study (Fig. 5.1B).
The pressure amplitudes and beam profiles of the FUS transducer were calibrated using a needle
hydrophone in a degassed water tank before the experiment. The reported pressure amplitudes
were corrected for 18% mouse skull attenuation [95]. The axial and lateral full-width-at-halfmaximum (FWHM) focal regions of the FUS transducer in the system were 6.04 mm and 0.62
mm, respectively.
The transducer was mounted to a 3D stage for precise positioning (Velmex, Lachine, QC,
Canada). The transducer was attached to a water balloon filled with degassed water to provide
acoustic coupling. The water balloon was immersed in a degassed water container, the bottom of
which featured a window sealed with an acoustically and optically transparent membrane
(Tegaderm; 3M, St. Paul, MN, USA). An ultrasound imaging probe (L8-14, working frequency
8-14 MHz, center frequency 12 MHz, Alpinion, Seoul, Korea) was inserted into the FUS
transducer center opening and aligned with the FUS focal plane.
Targeting of specific brain location was executed with the assistance of a grid [95]. The grid was
positioned in the water container on top of the mouse head with the crossing point in alignment
with the lambda, an anatomic landmark on the skull that is visible through the mouse skin on the
head. The ultrasound imaging probe was scanned through the grid to form a 3D B-mode
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ultrasound image of the grid using a customized Matlab (R2016b; Mathworks inc., Natick, MA,
USA) program. The crossing point of the grid was then identified and used as the reference point
to align the FUS focus at one selected point on the left side of the brainstem based on its
stereotactic location relative to the lambda (0 mm frontal and 1.5 mm to the left). The depth of
the FUS focus was adjusted to be 4.0 mm from the skull by measuring the distance from the
skull on the B-mode images.
Size-isolated microbubbles (median diameter of 4-5 µm) manufactured in-house [70] were
injected into the mice through the tail vein. For the FUSIN treatment, TR-AuNCs were
administered to the mice through the nose before the injection of microbubbles. For the FUSBBBD treatment, the TR-AuNCs were co-injected with the microbubbles. Immediately
following microbubbles injection, FUS treatment was performed. For both FUSIN and FUSBBBD, the following FUS treatment parameters were used: peak-negative pressure = 0.54 MPa,
pulse length = 6.7 ms, pulse repetition frequency = 5 Hz, and duration = 1 min. Four points
located at the corner of a square with side length of 0.5 mm and centered on the selected targeted
point were treated to enlarge the treatment volume.
Ex vivo fluorescence imaging
After FUSIN and FUS-BBBD treatment, mice were transcardially perfused at 30 min post-FUS
treatment in both groups (Fig. 5.1C). Mice in the IN only and IV only group were also perfused
at ~30 min after TR-AuNC administration. The blood was collected before the perfusion. After
perfusion, the brains were excised and sliced into 2-mm coronal sections using a brain matrix
(RBM-2000C; ASI Instruments, Inc., Warren, MI, USA). Other organs, including heart, lung,
spleen, kidney, liver, stomach, and intestine,
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were also harvested. The nasal tissue and

trigeminal nerves were carefully extracted from all groups of mice. The brain slices and all the
organs were examined using a fluorescence imaging system (Bruker Corporation, Billerica,
MA). The exposure time for the fluorescence imaging was kept the same for all the comparison
groups.
Inductively coupled plasma-mass spectrometry (ICP-MS) quantification
After the fluorescence imaging, the brain slices from the brainstem and forebrains were separated
and weighed. All the samples were transferred into 20 mL acid washed microwaveable digestion
tubes, and 0.4 mL aqua regia and 1.6 mL H2O2 were added to samples to predigest the sample
overnight. Then the samples were microwave-digested at 200oC for 60 min (20 min ramping and
20 min cooling) using an automated high-pressure microwave digestion system (Milestone Inc.
Monroe, CT). After digestion, 4 mL deionized water was added into every sample to make sure
the final acid concentration was less than 5% and ICP-MS (Elan DRC-e; Perkin Elmer, Rodgau,
Germany) analyses were performed at the Washington University Nano Research Facility. The
same aqua regia was processed similarly as blank control. Au standard was used to generate the
standard curve. The delivery efficiency of Au to the brain was expressed as the percentage of the
Au in the brainstem over the total injected Au normalized by the tissue weight (%ID/g). Results
were presented as the mean of three ICP-MS determinations for each data point. Following the
same procedure, all other dissected organs, as well as blood, nasal tissue, and trigeminal nerves
were processed for quantifying the concentration of AuNCs.
Histological analysis
The additional six mice were treated following the same protocol as described above. Mouse
brains were harvested from both groups after perfusion. The harvested brains were fixed in 4%
paraformaldehyde and embedded in paraffin. The brains were sectioned horizontally into 5 µm
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thick slices at 10 separate levels, with 180 µm intervals between two adjacent levels. At each
level, four sections were acquired and stained with hematoxylin and eosin (H&E). The mouse
noses were immersed overnight in a decalcifying solution before paraffin embedding. The nasal
tissue was also sectioned into 5 µm thicknesses and then stained with H&E. The trigeminal
nerves were fixed overnight in paraformaldehyde followed by cryoprotection with sucrose, then
sectioned into 10 µm sections and stained with Luxol fast blue-cresyl violet staining (LFB-CV).
Histological evaluation was performed single-blinded, by a trained observer without knowledge
of the location and parameters of sonication.
Statistical analysis
Statistical analysis was performed using GraphPad Prism (Version 5.01, La Jolla, CA, USA).
Differences between two groups were determined using a non-parametric Mann Whitney U Test.
A p-value <0.05 was used to determine statistical significance.

5.4 Results
Representative fluorescence images of the mouse brain slices and the quantification of the
delivery efficiencies of the TR-AuNCs to the brainstem and forebrain by FUSIN and FUSBBBD, as well as after IN or IV delivery are presented in Figure 5.2. The whole brain was cut
into six 2-mm slices. Slice 1 contains the olfactory bulb. Higher fluorescence intensity was
observed in slice 1 for FUSIN and IN groups, confirming successful IN administration of the
TR-AuNCs. Slice 5 was obtained at the FUS-targeted brain location. The fluorescence intensity
of slice 5 from the FUSIN group was significantly higher than the same slices from all other
groups. Based on ICP-MS quantification, the delivery efficiency of FUSIN to the brainstem was
found to be on average 25-fold higher than that of FUS-BBBD (p<0.001), 172-fold higher than
that of the IN only (p<0.001), and 549-fold higher than IV only (p<0.001). The ratio between
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AuNC delivery efficiency to the brainstem (slices 5 and 6 combined) and forebrain (slices 2–4
combined) was 16 with FUSIN and 7 with FUS-BBBD.
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Figure 5. 2: A) Fluorescence images (left panel) and corresponding photographs (right panel) of
representative ex vivo mouse brain slices. The targeted location of the FUS was located at slide 5
(highlighted by the boxes). B)

Quantification of the TR-AuNC delivery efficiency (%ID/g) to the

brainstem (slices 5 and 6 combined) and forebrain (slices 2–4 combined) of mice treated by FUSIN, FUSBBBD, IN only and IV only.

Figure 5.3A displays representative fluorescence images of major organs including heart, lung,
spleen, kidney, liver, stomach, and intestine collected from mice in the four groups. The
fluorescence signals in FUS-BBBD and IV groups were stronger in heart, lung, spleen, kidney,
and liver than those in FUSIN and IN groups. For the FUSIN and IN groups, the fluorescence
signals were only clearly observed in the stomach and intestines. Figure 5.3B summarizes the
quantified Au concentrations (%ID/g) in major organs. There was no significant difference
between FUSIN and IN, as well as between FUS-BBBD and IV, when comparing the measured
Au concentrations in all the measured organs. However, the Au concentrations were significantly
higher in most organs with FUS-BBBD than with FUSIN: heart (the ratio of the mean Au
concentrations: FUS-BBBD/FUSIN = 88.88; P<0.05), lung (ratio = 33.56; P<0.05), spleen (ratio
= 38.93; P<0.001), kidney (ratio = 63.44; P=0.54), and liver (ratio = 10.30; P=0.06). No
statistically significant difference was found in intestine (FUSIN/FUS-BBBD = 0.57, P=0.57).
Significant higher Au concentration associated with FUSIN was observed only in the stomach
(FUSIN/FUS-BBBD=18.28; P<0.001).
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Figure 5. 3: A) Fluorescence images (left panel) and corresponding photographs (right panel) of
dissected mouse organs of mice treated by FUSIN, FUS-BBBD, IN only and IV only. B) Quantifications
of the TR-AuNC distribution in major organs.

Strong fluorescence signals were observed in the nasal tissue and trigeminal nerves from the
FUSIN group, but not the FUS-BBBD group (Fig. 5.4A). Au concentration in the nasal tissue
and trigeminal nerves were respectively 290-fold and 72-fold higher in the FUSIN group than
those of the FUS-BBBD group (Fig. 5.4B). However, the gold concentration in the blood was
109-fold higher in the FUS-BBBD group than that of the FUSIN group.

Figure 5. 4: A) Fluorescence images (left panel) and corresponding photographs (right panel) of
dissected mouse nasal tissue and trigeminal nerves from mice treated with FUSIN and FUS-BBBD. The
blue color visible in the photograph of the nasal tissue obtained from the FUSIN group is the color of the
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Texas red. B) Quantifications of the TR-AuNC distribution in the trigeminal nerve, nasal tissue, and
blood.

H&E staining of the nasal sections showed no damage to nasal tissue in either the FUSIN group
(Fig. 5.5A) or the FUS-BBBD group (Fig. 5.5B). The LFB-CV stained trigeminal nerve sections
from both groups did not find a histological-level change of the nerve (Figs. 5.5C and D). No
hemorrhage was observed in the FUSIN-treated brainstem (Fig. 5.5E) and the FUS-BBBD
treated brainstem (Fig. 5.5F).
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Figure 5. 5: Histological examinations by H&E staining of the mouse nose, trigeminal nerve, and
brainstem of mice treated with FUSIN (left column) and FUS-BBBD (right column). No histological-level
tissue damage was observed in the nasal tissue, trigeminal nerve, and brainstem of all treated mice.

5.5 Discussion
FUSIN is a newly developed brain drug delivery technique. This study compared FUSIN
delivery efficiency, systemic exposure, and delivery routes with those of the more established
FUS-BBBD technique. FUSIN achieved higher delivery efficiency to the brainstem and lower
systemic exposure in most organs compared with FUS-BBBD. This study also verified that
FUSIN delivered TR-AuNCs mainly through the nose-to-brain route, which was different from
the blood-to-brain pathway utilized by FUS-BBBD.
FUS-BBBD has been used to successfully deliver a wide range of agents across the BBB to the
brain, including various nanoparticles [82,83,86–88,166,167]. This study found that FUSIN
achieved significantly higher delivery efficiency than FUS-BBBD for the delivery of TR-AuNCs
to the brainstem. The delivery efficiency of FUSIN was on average 25-fold higher than that of
FUS-BBBD (Fig. 5.2). The higher delivery efficiency achieved by FUSIN indicated that FUSIN
and FUS-BBBD are different not only in the agent delivery route (IN vs. IV) but also the
delivery mechanism. Olfactory nerve and trigeminal nerve endings in the nose cavity normally
act as chemical sensors for detecting scents. This unique and important anatomic arrangement
offers a route for direct medication delivery into the brain. Based on the rapid speed of transport
from the nose to brain structures, bulk transport along the channels surrounding the olfactory and
trigeminal nerves is the most likely mechanism for nose-to-brain transport [145]. Once inside the
brain entry points (i.e., olfactory bulb and brainstem), the IN administered agents are distributed
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in the whole brain along the cerebral perivascular spaces – thin annular regions surrounding the
blood vessels – and may be propelled through the perivascular spaces by heartbeat-driven
pulsations of the blood vessel walls, called the “perivascular pump effect” [138]. Based on our
previous work on ultra-high-speed photomicrography of microbubble dynamics in ex vivo
microvessels [74], we observed that microbubble oscillations push and pull on the blood vessel,
which leads to expansion and contraction of the vessel and surrounding tissue. Based on the
similarity of this phenomenon with the perivascular pump effect, we hypothesized that the
“microbubble pump effect” may be the potential mechanism for FUSIN. Additionally, our study
also revealed that FUSIN treatment at the brainstem was associated with enhanced agent delivery
to other parts of the brain at 30 min after the treatment. We speculate that the cause of the
enhanced delivery to the non-treated brain was associated with diffusion of TR-AuNCs from the
brainstem to other locations due to the accumulation of TR-AuNC with a high concentration in
the brainstem and the small volume of the mouse brain. Nevertheless, the ratio between the Au
concentrations in the FUSIN-treated brain locations was 16-fold higher than that of the nontreated forebrain, indicating that by decreasing the IN-administration dose, FUSIN can achieve
the therapeutic delivery level only within the treated site while keeping non-treated sites at nontoxic levels. Future study is needed to reveal the pharmacokinetics of agents delivered by
FUSIN.
This study found that FUSIN delivery efficiency was 172-fold higher than that of IN only for the
delivery of TR-AuNCs to the brainstem. These findings confirmed that IN administration is
limited by the low delivery efficiency to the brain and demonstrated that FUSIN significantly
improved the delivery efficiency of TR-AuNCs compared with IN only. Previous studies already
demonstrated enhanced delivery of dextrans and brain-derived neurotrophic factor to the caudate
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putamen by FUSIN [70,96]. The current study is important in expanding the applications of the
FUSIN technique. First, it showed that FUSIN could be used for the efficient delivery of
nanomedicines to the brain. The low delivery efficiency of nanoparticles to the brain has been
the major challenge for brain theranostics. Our finding opens new opportunities for the
development of nanomedicine in the treatment of brain diseases. Second, this study suggested
that FUSIN is a promising technique for delivering agents to different brain locations. Previous
studies have shown that FUSIN can be used for spatially localized delivery of agents to the
caudate putamen. This study presented successful agent delivery to the brainstem. The brainstem
is unique for IN delivery as it is directly connected with the nasal mucosa through the trigeminal
nerve. Future study is needed to compare the delivery efficiency of FUSIN at the brainstem with
other parts of the brain to assess the brain location dependency of FUSIN.
Regarding systemic exposure, it is known that IN administration can deliver agents directly from
the nose to the brain, minimizing the systemic exposure. This study verified that IN
administration of TR-AuNCs was associated with low systemic exposure. The systemic
distribution associated with FUSIN was not significantly different from IN only, suggesting that
the effect of FUS was only localized to the brain without affecting the systemic biodistribution of
the TR-AuNCs. The ICP-MS quantification found that FUS-BBBD was associated with 10–90
fold higher Au concentrations than those of FUSIN in the heart, lung, spleen, kidney, and liver,
but not the stomach and intestine. The high concentration of TR-AuNCs in the stomach and
intestine suggested that IN administered TR-AuNCs was removed by the mucus to the
nasopharynx, which resulted in TR-AuNCs accumulating in stomach and intestine. It allows the
TR-AuNCs to be excreted from the animal through feces, leading to minimized systemic toxicity
[168]. The Au concentration in the stomach had a high standard deviation, which was due to the
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high variability of mice in mucociliary clearance and digestion [145]. It is noted that the
quantification of intestinal exposure was limited by the relatively small piece of the whole
intestine that was dissected for ICP-MS quantification. This is in contrast to ICP-MS
quantification of other organs in which the entire organ was utilized.
The agent delivery routes of FUSIN and FUS-BBBD were confirmed to be different. For FUSBBBD, it is known that the FUS in combination with microbubbles can disrupt the BBB,
allowing agents to be delivered through the blood-to-brain route: agents in the blood circulation
are delivered across the BBB and accumulate in the FUS-targeted brain region where the BBB is
disrupted. For FUSIN, there are two potential routes for brain drug delivery: (1) nose-to-brain
route: transportation of agents through the olfactory and trigeminal nerves directly to the brain;
(2) blood-to-brain route: agents may be absorbed into the systematic circulation through the
highly vascularized nasal mucosa and reach the brain through the disrupted BBB. Our findings
confirmed that FUSIN delivered TR-AuNCs mainly through the nose-to-brain route, instead of
the blood-to-brain route because the Au concentration in the blood was two orders of magnitude
lower in the FUSIN group than the FUS-BBBD group. The higher delivery efficiency achieved
by FUSIN compared with FUS-BBBD suggested that the FUS-mediated agent delivery through
the nose-to-brain route had higher delivery efficiency than the blood-to-brain route. The higher
delivery efficiency by FUSIN may be related to the advantages of the nose-to-brain pathway: (1)
direct access to the brain with minimal hepatic clearance; (2) bypassing the BBB, which avoids
the need to cross the BBB and overcome the efflux system [169]. Future studies are needed to
understand why FUSIN can achieve higher delivery efficiency than FUS-BBBD.
This study has several limitations. First, only TR-AuNCs were used in this study. Studies are
needed to explore the effect of nanoparticle characteristics, such as size, surface charge, and
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material, on the FUSIN delivery efficiency and systemic exposure. Second, all the comparisons
between FUSIN and FUS-BBBD were conducted at a single time point (30 min) after the FUS
treatment. Although we do not expect measurements at more time points will change our
conclusions, a comprehensive comparison study at multiple time points are needed to fully
understand the pharmacokinetics of agent delivered by these two approaches. Last but not least,
the mechanism of FUSIN delivery is not clear. Future study is needed to understand nanoparticle
transport mechanisms in the brain by FUSIN.

5.6. Conclusion
FUS-BBBD has been established as a promising technique for noninvasive and localized
delivery of various imaging or therapeutic agents across the BBB. FUSIN is a new technique for
brain drug delivery by integrating FUS and microbubbles to enhance the accumulation of
intranasally administered agents at the FUS-targeted brain location. This study found that FUSIN
achieved one order of magnitude higher delivery of TR-AuNCs to the brainstem and one order of
magnitude lower distribution in other major organs than those of FUS-BBBD. It also verified
that FUSIN delivered the TR-AuNCs through the nose-to-brain route, different from FUS-BBBD
which utilized the blood-to-brain route. Histological analysis did not find any histological-level
damage to the nose, trigeminal nerve, and brain. These findings suggest that FUSIN is a
promising technique for noninvasive, efficient, and localized delivery of nanoparticles to the
brainstem with minimal systemic exposure.
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Chapter 6: Optimization of focused ultrasoundmediated brainstem delivery of intranasally
administered agents
6.1 Abstract
Focused ultrasound-mediated intranasal (FUSIN) delivery is a recently proposed technique that
bypasses the blood-brain barrier to achieve noninvasive and localized brain drug delivery. The
goal of this study was to characterize FUSIN drug delivery outcomes in mice with regard to its
dependency on several critical experimental factors, including the time interval between IN
administration and FUS sonication (Tlag1), the FUS pressure, and the time for sacrificing the mice
post-FUS (Tlag2). Wild-type mice were treated by FUSIN delivery of near-infrared fluorescent
dye-labeled bovine serum albumin (800CW-BSA, used as a model agent). 800CW-BSA was
intranasally administered to the mice in vivo, followed by intravenous injection of microbubbles
and FUS sonication at the brainstem. Fluorescence imaging of ex vivo mouse brain slices was
used to quantify the delivery outcomes of 800CW-BSA. Major organs, along with the nasal
tissue and trigeminal nerve, were harvested to assess the biodistribution of 800CW-BSA. The
delivery outcome of 800CW-BSA was the highest at the brainstem when Tlag1 was 0.5 h, which
was on average 24.5-fold, 5.4-fold, and 21.6-fold higher than those of the IN only, Tlag1 = 1.5 h,
and Tlag1 = 4.0 h, respectively. The FUSIN delivery outcome at the lowest pressure level, 0.43
MPa, was on average 1.8-fold and 3.7-fold higher than those at 0.56 MPa and 0.70 MPa,
respectively. The mean concentration of 800CW-BSA in the brainstem after FUSIN delivery
decreased from 0.5 h to 4.0 h post-FUS. The accumulation of 800CW-BSA was low in the heart,
lung, spleen, kidneys, and liver, but high in the stomach and intestines. This study revealed the
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unique characteristics of FUSIN as a noninvasive, efficient, and localized brain drug delivery
technique.

6.2 Introduction
Transcranial focused ultrasound (FUS) in combination with microbubbles has been used for
noninvasive, localized, and reversible blood-brain barrier (BBB) disruption (FUS-BBBD) to
enhance the delivery of intravenously injected drugs to FUS-targeted brain sites [35]. FUS
noninvasively penetrates the skull and focuses on a small focal region of millimeter-scale
dimensions. Microbubbles, which have been used in the clinic as ultrasound contrast agents for
imaging, are administered by intravenous (IV) injection. After IV injection, they are confined to
the vasculature due to their relatively large sizes (1–10 μm). Microbubbles amplify and localize
FUS-mediated mechanical effects on the vasculature through FUS-induced cavitation (i.e.,
microbubble expansion, contraction, and collapse), which generates mechanical forces on the
vasculature [37] and transiently increases BBB permeability. FUS-BBBD has been used to
deliver a wide range of therapeutic agents across the BBB to the brain, such as small molecule
drugs [170], protein drugs [48,50], viruses [51,171,172], and even cells [53,54]. Early phase
clinical trials have demonstrated the feasibility and safety of FUS-BBBD in patients with
glioblastoma [173–175], Alzheimer's disease [56,176,177], and amyotrophic lateral sclerosis
[57]. Although promising, this technique requires therapeutic agents to be injected through the
IV route, which is associated with systemic exposure of the agents to the whole body.
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Intranasal (IN) drug delivery provides an alternative route for drug administration to the brain
because it is a painless, simple, and noninvasive approach that allows direct agent delivery from
the nose to the brain. It bypasses the BBB and eliminates the need for systemic delivery, thereby
minimizing associated side effects. IN-administered drugs use two major routes to reach the
brain – one through the olfactory nerve to the olfactory bulb, and the other through the trigeminal
nerve to the brainstem. Therefore, IN delivery holds a unique advantage, especially for drug
delivery to the brainstem. When the administered agents reach the brain entry points, they can be
transported along the perivascular space by the "perivascular pump effect," which arises from
heartbeat-driven pulsation (expansion and contraction) of blood vessel walls [138,178,179]. IN
administration has already been used for the delivery of a wide range of therapeutics to the brain
(e.g., peptides [180], proteins [141], gene vectors [161,181], nanoparticles [18,182], and stem
cells [163]), not only in animal studies but also in humans [164]. However, two major limitations
– low delivery efficiency and lack of disease-site targeting – prevent its broad and successful
application in translational research [68,183].
FUS-mediated intranasal (FUSIN) delivery is a recently proposed brain drug delivery technique
that capitalizes on the unique advantages of the IN route for direct nose-to-brain drug
administration as well as FUS in combination with microbubbles for targeted and enhanced
delivery to the brain [70,71,96,184]. FUS-induced microbubble cavitation pushes and pulls on
the adjacent blood vessel [74], generating the proposed "microbubble pump effect" [184]. The
microbubble pump effect may lead to the enhanced penetration and accumulation of INadministered drugs distributed in the perivascular space. FUSIN was first reported in 2014 and
showed improved delivery of dextrans and a protein drug (brain-derived neurotrophic factor) to
the FUS-targeted caudate-putamen of mouse brains [70,96]. It was also used to deliver
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fluorescently labeled gold nanoclusters and radiolabeled gold nanoclusters to the brainstem
[184]. A recent study reported that FUSIN delivery of the brain-derived neurotrophic factor
produced neuro-restorative effects in a Parkinson's disease mouse model [71]. All these previous
findings suggest that FUSIN is a promising brain drug delivery technique that can locally
enhance the delivery efficiency of different agents to various brain regions.
The objective of the current study was to characterize the dependency of FUSIN drug delivery
outcome on several critical experimental parameters, including the time interval between IN
administration and FUS application, the FUS pressure, and the sampling time (the waiting time
after FUS treatment to sacrifice the mouse). We selected fluorescently labeled albumin as the
model agent because it has been widely used as a model agent to study protein-drug
pharmacokinetics [185,186], and previous studies have used it to quantify the BBB permeability
[187,188].

6.3 Materials and methods
Animals and study design
All animal procedures were reviewed and approved by the Institutional Animal Care and Use
Committee in accordance with the National Institutes of Health Guidelines for animal research.
Cr.NIH (Swiss) mice (6–8 weeks, ~25 g body weight, female) were purchased from Charles
River Laboratory (Wilmington, MA, USA). The animals were housed in a room maintained at
22oC and 55% relative humidity, with a 12-h/12-h light/dark cycle and access to standard
laboratory chow and water. A total of 48 mice (Table 6.1) were used to study the dependency of
FUSIN delivery outcome on the time interval between IN administration and FUS sonication, the
FUS pressure, and the sampling time after FUS treatment. This study followed a one-factor-at-a102

time (OFAT) experimental design as the three tested parameters (Tlag1, Tlag2, and pressure), which
represented key experimental parameters at different stages of the experimental procedures (Fig.
6.1 D), were expected to not interfere with each other. The justifications for the study design are
described below.
Based on our previous study [70], FUS treatment applied after IN administration achieved higher
delivery efficiency than FUS applied before IN administration. However, the dependency of
FUSIN delivery on the time interval between IN and FUS (Tlag1, defined as the time interval
between the end of IN administration and the beginning of FUS sonication) had not been
evaluated. This study chose three different time intervals, Tlag1 = 0.5 h, 1.5 h, and 4.0 h, in
reference to a previous study that reported the pharmacokinetics of IN-delivered albumin in
different brain locations [189]. Specifically, it showed that albumin concentration in the pons,
which is part of the brainstem, significantly decreased as time increased at these three time points
post-IN: 0.5 h, 1.5 h, and 4.0 h. Mice in groups 2 – 4 (Table 6.1) were used to study the effect of
Tlag1. The control group (group 1) was administered with 800CW-BSA without FUS. The
pressure was selected to be 0.56 MPa because this pressure led to successful and safe FUSIN
delivery in our previous reported study [184] and pressure levels at around 0.5 MPa have been
shown to be safe for FUS combined with microbubble applications in the mouse brain [159,190].
FUS treatment is controlled by multiple parameters, such as FUS frequency, acoustic pressure,
pulse length, pulse repetition frequency, and sonication duration. The peak-negative pressure is a
critical parameter, if not the most important one, that is directly related to the microbubble
cavitation activities in FUS treatment. The mechanical index (MI) calculated by the peaknegative pressure divided by the square root of the center frequency has been commonly used to
predict the likelihood of cavitation. Recently, Bader et al. derived the cavitation index (CI),
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defined as the peak-negative pressure divided by the center frequency, to gauge the likelihood of
subharmonic emissions due to microbubble stable cavitation [29,30]. Moreover, the peaknegative pressure has been found in many previous FUS combined with microbubbles mediated
drug delivery studies to have a significant correlation with the drug delivery outcome
[100,191,192]. Therefore, the current study focused on assessing the impact of the peak-negative
pressure on FUSIN. Mice in groups 2, 7, and 8 (Table 6.1) were used to evaluate FUSIN delivery
under three acoustic pressure levels centered around 0.56 MPa: 0.43 MPa, 0.56 MPa, and 0.70
MPa. These pressure levels were similar to those commonly used in FUS-BBBD studies
[159,190,193].
In order to examine the pharmacokinetics and clearance of agents delivered by FUSIN, three
groups of mice were perfused at different time points post-FUS (Tlag2, defined as the time
interval between the end of FUS sonication and the beginning of animal sacrifacing procedure).
Mice in groups 2, 5, and 6 (Table 6.1) were used to study the impact of the sampling time: Tlag2 =
0.5 h, 1.0 h, and 4.0 h. We harvested the mouse brains and other major organs (heart, lung,
spleen, kidneys, liver, stomach, intestines) and dissected the nose tissue and trigeminal nerve to
evaluate the biodistribution and kinetics of FUSIN-delivered agents.
Table 6. 1: Summary of all study groups.
Group #
Animal #
Tlag1*
Pressure
Tlag2*
Control (IN only)
1
6
2
6
0.5 h
0.56 MPa
0.5 h
3
6
1.5 h
0.56 MPa
0.5 h
4
6
4.0 h
0.56 MPa
0.5 h
5
6
0.5 h
0.56 MPa
1.0 h
6
6
0.5 h
0.56 MPa
4.0 h
7
6
0.5 h
0.43 MPa
0.5 h
8
6
0.5 h
0.70 MPa
0.5 h
* Tlag1: Time delay between IN and FUS; Tlag2: Time of sacrifice after FUS
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Near-infrared fluorescent dye-labeled bovine serum albumin (800CW-BSA)
Biotin

and

800CW

(LI-COR

Biosciences,

Lincoln,

NE)

were

activated

with N-

hydroxysuccinimide (NHS) ester and conjugated to the BSA by the amide bond through
EDC/NHS (1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide/N-hydroxysuccinimide) chemistry.
The amide bond is one of the most abundant chemical bonds with high stability in various
reaction conditions. It widely exists in many organic molecules, including peptides, proteins,
DNA and RNA [194]. The EDC/NHS chemistry has been commonly used in both preclinical and
clinical studies to label peptides, proteins, and antibodies with near-infrared (NIR) dyes,
including 800CW [195–201]. Specifically, in pH 7–9 buffers, NHS esters react efficiently with
primary amino groups (-NH2) by the nucleophilic attack, forming an amide bond and releasing
the NHS. 2 mg of NHS-activated biotin (NHS-PEG4-Biotin, Thermo Scientific, Prod #: 21329)
was added to 2.2 mL of BSA (Sigma-Aldrich, A7030) solution (5 mg/mL in 1× PBS). The
mixture was incubated at room temperature (~22°C) for 1 hour to complete the reaction. Excess
NHS-PEG4-Biotin was removed from the solution using a desalting column (5 mL, 7000
MWCO, Thermo Scientific, Prod #: 21329) pre-equilibrated with 1× PBS. The 800CW was
conjugated to BSA-biotin following the manufacturer's protocol for labeling high molecular
weight proteins (LI-COR Biosciences, Lincoln, NE). 0.1 mL of 1 M potassium phosphate buffer
(K2HPO4, pH = 9) was added into 1 mL of purified BSA-biotin solution to raise the pH. Next,
25 µL of 4 mg/mL NHS-800CW (Licor, 929-70020) was added to the mixture, and the solution
was incubated at 23°C for 2.5 hours. Free NHS-800CW was then separated from the conjugate
using a Zeba desalting column (Thermo Fisher Scientific). After purification, 800CW-BSA was
collected for the FUSIN delivery. The final concentration of BSA was determined using the
NanoDrop-2000 (Thermo Fisher Scientific, Wilmington, DE, USA). The collected 800CW-BSA
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was diluted in saline by factors of 50, 100, 200 and 400 and imaged by the Pearl Image
System (LI-COR Biosciences, Lincoln, NE). The results verified that the fluorescence intensity
of 800CW detected by the Pearl Imaging System was linearly correlated with the BSA
concentration (Fig. 6.1F).
IN administration
The IN administration procedure was the same as reported before [70]. Mice were placed supine
under anesthesia. Drops (3 µL each) of 800CW-BSA (concentration ~1.3 mg/mL) were
administered to the mouse nose, alternating between the left and right nostrils every 2 mins.
These drops were placed at the opening of the nostril, allowing the animal to snort each drop into
the nasal cavity. A total of 8 drops (24 µL) were administered to each mouse.
FUS treatment
An ultrasound image-guided FUS system (VIFU 2000; Alpinion US Inc., Bothell, WA, USA)
consisting of a FUS transducer with a center frequency of 1.5 MHz, a focal depth of 60 mm, an
aperture of 60 mm, and a circular central opening of 38 mm was used in this study (Fig. 6.1A
and 6.1B). The pressure amplitudes and beam profiles of the FUS transducer were calibrated
using a needle hydrophone in a degassed water tank before the experiment. The reported
pressure amplitudes were corrected for 18% mouse skull attenuation [95]. The axial and lateral
full-width-at-half-maximum (FWHM) focal regions of the FUS transducer in the system were
6.04 mm and 0.62 mm, respectively. An ultrasound imaging probe (L8-17, working frequency 8
–17 MHz, center frequency 12 MHz, Alpinion, Seoul, Korea) was inserted into the FUS
transducer center opening and aligned with the FUS focal plane. FUS was targeted at the right
side of the brainstem under the guidance of ultrasound imaging using the L8-17 probe with the
assistance of a grid [126].
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The animal was stabilized by a stereotaxic frame in the prone position after the IN administration
to prepare for FUS treatment (Fig. 6.1B). The fur on the mouse head was removed, and a water
container filled with degassed water was placed on the mouse head and coupled with degassed
ultrasound gel for FUS coupling. The bottom of the water container had a window sealed with a
transparent membrane (Tegaderm®, 3M Health Care, St. Paul, MN, USA). The FUS transducer
was attached to a water balloon filled with degassed water. The water balloon was immersed in
the water container to provide acoustic coupling (Fig. 6.1A and B). A tail vein catheter was
inserted into the mouse tail vein for the injection of microbubbles. The time normally needed to
finish the above mouse preparation was 0.5 hours. Size-isolated microbubbles (median diameter
of 4–5 µm) manufactured in-house [202] were injected through the tail vein, and this was
immediately followed by FUS sonication. FUS sonication was performed at different time points
after IN administration (Tlag1 = 0.5 h, 1.5 h, and 4.0 h) (Fig. 6.1D). The following FUS
parameters were used: pressure = 0.43 MPa, 0.56 MPa, or 0.70 MPa, pulse length = 6.7 ms,
pulse repetition frequency = 5 Hz, and duration = 1 min. Four points located at the corners of a
square with a side length of 0.6 mm were treated in order to enlarge the treatment volume. Mice
were transcardially-perfused at different time points post-FUS treatment (Tlag2 = 0.5 h, 1.0 h, and
4.0 h). Mice in the control group (group 1) were perfused at ~1.0 h after IN administration of
800CW-BSA.
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Figure 6. 1: Experimental methods. (A) A schematic and (B) picture of the FUS system for mouse brain
treatment. Illustration of the (C) FUSIN procedure and (D) experimental timeline. IN delivery of 800CWBSA was followed by FUS treatment targeting at the brainstem. (E) After FUSIN treatment, the mouse
brain was harvested and cut into 2-mm coronal slices for fluorescence imaging. The high fluorescence
intensity observed at the olfactory bulb confirmed that IN-administered 800CW-BSA transport to the
brain along the olfactory pathway. (F) 800CW-BSA fluorescence intensity at different dilutions showed a
linear relationship between fluorescence intensity and the concentration of 800CW-BSA.
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Ex vivo fluorescence imaging and analysis
After perfusion, the brains were excised and sliced into 2-mm coronal sections using a brain
matrix (RBM-2000C; ASI Instruments, Inc., Warren, MI, USA) (Fig. 6.1E). The nose, trigeminal
nerve, heart, lung, spleen, kidney, liver, stomach, and intestines were harvested in groups 2, 5,
and 6 to study the biodistribution of 800CW-BSA at different time points. The brain slices and
all organs were examined by the Pearl Imaging System using the 800 nm channel for 800CWBSA (Fig. 6.1E). The Pearl Imaging System offers in vivo imaging in the NIR range (700 – 900
nm), where tissue autofluorescence and absorption are low. This system allows a wide dynamic
range (22 bits) capture, which can image samples with fluorescence intensity of a million-fold
difference and avoid saturation or underexposure [203]. The exposure time for fluorescence
imaging was kept the same (30 s) for all groups. The fluorescence intensity of the brain slices
and organs were quantified using LI-COR's Image Studio Lite software by an experimenter
blinded to experimental conditions.
Histologic analysis
Our previous study of FUSIN delivery showed that FUS treatment at an acoustic pressure of 0.56
MPa did not cause histological damage to the mouse brainstem [184]. In this study, three
different pressures (0.43 MPa, 0.56 MPa, and 0.70 MPa) were used for FUSIN treatment. We
performed histologic examinations of mice treated with 0.70 MPa using hematoxylin and eosin
(H&E) staining and compared with control mice without treatment (groups 1 and 8 as listed in
Table 6.1). After fluorescence imaging of the 2-mm thick brain slices, the mouse brainstems
were fixed in 4% paraformaldehyde overnight, followed by cryoprotected with sucrose. The
brainstems were sectioned coronally into 15 µm sections and stained with H&E. Histological
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evaluation was performed single-blinded by an observer without knowledge of the location and
parameters of sonication.
Statistical analysis
Statistical analyses were performed using R statistical software v3.5.0 (https://www.Rproject.org/), and figures were produced using GraphPad Prism (Version 8.3, La Jolla, CA,
USA). Differences among groups were determined using a non-parametric Kruskal-Wallis test
(one-way ANOVA on ranks) followed by post hoc non-parametric Mann-Whitney U tests for
group-wise comparisons. P-value < 0.05 was used to determine statistical significance.

6.4 Results
Impact of the time interval between IN and FUS (Tlag1)
Representative fluorescence images of the mouse brain slices and the corresponding
quantification of 800CW-BSA fluorescence intensity in the brainstem for each group are
presented in Figure 6.2. Among the groups treated with FUS after IN administration with
different Tlag1 and non-treated control group, there was a significant between-group difference in
fluorescence intensity (n = 24; four groups; Kruskal-Wallis chi-squared = 15.1, df = 3, p =
0.0018). The delivery outcome of 800CW-BSA in the Tlag1 = 0.5 h group as indicated by the
measured fluorescence intensity was found to be on average 24.5-fold, 5.4-fold, and 21.6-fold
higher than those in the controlled IN only, Tlag1 = 1.5 h, and Tlag1 = 4.0 h groups, respectively
(Fig. 6.2B). FUS applied at 1.5 h and 4.0 h post-IN administration did not show a significant
difference in the delivery outcomes when compared with IN only.
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Figure 6. 2: FUSIN delivery of 800CW-BSA to the brainstem at different time intervals between IN and
FUS (Tlag1) (groups 1, 2, 3, and 4 in Table 6.1). (A) Fluorescence images, bright field images, and their
overlays of representative ex vivo mouse brainstem slices at different Tlag1. (B) Quantification of the
800CW-BSA fluorescence intensity at the brainstem for groups with different Tlag1 and the control (IN
only) group without FUS (Mann–Whitney U test; **: P < 0.01;ns: not significant). The scale bar is 5 mm.

Impact of FUS pressure
A significant group effect was observed on fluorescence intensity among the FUS-treated mice
with different acoustic pressures (0.43 MPa, 0.56 MPa, and 0.70 MPa) and the non-treated
control mice (n = 24; four groups; Kruskal-Wallis chi-squared = 16.1, df = 3, p = 0.0011).
Overall, the FUS-treated groups showed significantly higher fluorescence intensity compared to
the mice in the IN-only group (Fig. 6.3). Mice treated with 0.43 MPa demonstrated 1.8-fold and
3.7-fold higher mean fluorescence intensity than those treated with 0.56 MPa and 0.70 MPa,
respectively (Fig. 6.3B). Exploratory analysis revealed a negative correlation between the
fluorescence intensity and FUS pressure (among the FUS-treated mice: n=18; Kendall tau-b
correlation = -0.45, p = 0.021).
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Figure 6. 3: FUSIN delivery of 800CW-BSA to the brainstem at different FUS pressure levels (groups 1,
2, 7, and 8 in Table 6.1). (A) Fluorescence images, bright field images, and their overlays of
representative ex vivo mouse brain slices of the brainstem at different pressure levels. (B) Quantification
of the 800CW-BSA fluorescence intensity for different pressure groups and the control (IN only) group
without FUS (Mann–Whitney U test; *: P < 0.05; **: P < 0.01; ns: not significant). The scale bar is 5
mm.

Impact of the sacrifice time post-FUS (Tlag2)
Significant between-group difference in fluorescence intensity was observed (Kruskal-Wallis
chi-squared = 10.2, df = 2, p = 0.006) among mice with different sacrifice times post-FUS (n =
18; three groups: Tlag2 = 0.5 h, 1.0 h, and 4.0 h). The brainstem retention of 800CW-BSA was
similar at Tlag2 = 0.5 h and Tlag2 = 1.0 h post-FUS, while at Tlag2 = 4.0 h, the average retention of
800CW-BSA had dropped by 5.5-fold and 4.9-fold compared to at 0.5 h and 1.0 h, respectively
(Fig. 6.4B).
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Figure 6. 4: The pharmacokinetics of FUSIN-delivered 800CW-BSA at the brainstem (groups 2, 5, and 6
in Table 6.1). (A) Fluorescence images, bright field images, and their overlays of representative ex vivo
mouse brain slices at the brainstem of mice sacrificed at different Tlag2. (B) Quantification of the 800CWBSA fluorescence intensity for different Tlag2 groups (Mann–Whitney U test; **: P < 0.01; ns: not
significant). The scale bar is 5 mm.

Systemic exposure associated with FUSIN
Figure 6.5A displays representative fluorescence images of major organs, including the heart,
lung, spleen, kidneys, liver, stomach, and intestines, as well as the nose and trigeminal nerve
collected from mice sacrificed at the three different Tlag2 times post-FUS. Figure 6.5B shows the
corresponding quantification results. In terms of 800CW-BSA distribution in organs, the
fluorescence signals were mainly observed in the stomach and intestines, with fluorescence
intensity about two orders of magnitude higher than in other organs. The fluorescence signal was
higher at 4.0 h compared to at 0.5 h and 1.0 h in the stomach and intestines. The 800CW-BSA
also accumulated in the nose and trigeminal nerve; however, in contrast to the stomach and
intestines, the amount of 800CW-BSA at 4.0 h was decreased by 62% and 87%, respectively, in
the nose and trigeminal nerve compared to at 0.5 h.
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Figure 6. 5: The biodistribution and kinetics of 800CW-BSA delivered by FUSIN (groups 2, 5, and 6 in

Table 6.1). (A) Fluorescence images of major organs, nose, and the trigeminal nerve at different Tlag2. (B)
Quantification of 800CW fluorescence intensities in major organs, nose, and the trigeminal nerve at
different Tlag2.
H&E staining
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Representative H&E staining of the FUS-treated side of the brainstem showed no hemorrhage or
neuron damage at the highest tested acoustic pressure level (0.70 MPa) compared with the
control without treatment (Fig. 6.6). No tissue damage was consistently observed in all the H&Estained mouse brain slices.

Figure 6. 6: Representative histological examination of the brainstems of (A) FUSIN-treated mouse at
0.70 MPa (group 8 in Table 6.1) and (B) non-treated control mouse (group 1 in Table 1), showing that
FUSIN treatment did not induce hemorrhage or neuron damage. (C) and (D) are the zoomed-in views of
the regions labeled with the boxes in (A) and (B), respectively.
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6.5 Discussion
This study characterized the FUSIN brain drug delivery technique by evaluating the impact of
critical experimental factors, including the time interval between IN and FUS, the FUS pressure,
and the sampling time after FUS treatment. Findings from this study revealed that FUSIN
delivery outcome depends on these critical experimental parameters, providing insights for
selecting optimal treatment parameters, and shinning light on the potential mechanisms of
FUSIN.
A previous study performed FUS either before or after the IN delivery of a fluorescently labeled
dextran and found that FUS enhanced the delivery only when applied after IN, while the
pretreatment by FUS followed by IN did not show significantly enhanced delivery compared
with IN only. This previous finding suggested that FUS could enhance the accumulation of INadministered agents when the agents have already existed in the FUS-targeted brain region [70].
A recent FDA approved device for enhancing transdermal delivery, Low-Frequency
Sonophoresis (LSF), requires the agents to be administered after sonication. LSF utilizes the
violent collapse of cavitation bubbles (i.e., inertial cavitation) to produce microjets and
microstreaming that can disrupt the lipid bilayers of the stratum corneum microscopically in the
transdermal delivery [204]. Moreover, LSF can lead to a typical temperature increase of ~10°C
[205,206]. Both inertial cavitation and the associated thermal effects may change the properties
of the therapeutics; therefore, agents are administered after ultrasound sonication. However,
FUSIN uses FUS with intensity at the diagnostic ultrasound range and the physical mechanism is
stable cavitation as the pressure is often below inertial cavitation threshold in the mouse brain
[100]. Stable cavitation is utilized instead of inertial cavitation to avoid any potential damage to
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the sensitive brain tissue. The gentle mechanical oscillation should have a low chance of
changing the therapeutics, allowing the agents to be administered before FUS sonication. The
current study performed IN followed by FUS and examined the impact of the time interval
between IN and FUS (Tlag1). It was found that FUSIN delivery of 800CW-BSA to the brainstem
reached the greatest accumulation at 0.5 h among the three tested Tlag1, and decreased as Tlag1
increased to 1.5 h and 4.0 h (Fig. 6.2). It was reported before that concentration of IN
administerd albumin at the brainstem significantly decreased as time increased from 0.5 h to 4.0
h post-IN [189]. Combing this report and our finding, it implies that FUSIN achieves greater
delivery when FUS is applied as the IN-administered agent reaches higher concentration in the
targetd brain region. The Tlag1 needs to be selected in consideration of the pharmacokinetics of
the IN-delivered agents in the brain.
Although both FUSIN and FUS-BBBD are FUS-mediated brain drug delivery techniques, and
both can achieve enhanced drug delivery to the targeted brain location, the correlations between
their delivery efficiency and the acoustic pressure exhibit opposite trends. Based on previous
reports, the efficiency of FUS-BBBD delivery mainly depends on acoustic pressure. Higher
pressure is associated with a higher increase in BBB permeability and thus improved efficiency
of trans-BBB delivery [35,100,207–209]. However, in this study, the amount of 800CW-BSA at
the brainstem delivered by FUSIN decreased with higher FUS pressure (Fig. 6.3). This finding
supports our hypothesis that FUSIN achieves enhanced drug delivery not by increasing the BBB
permeability but through another mechanism. Our proposed "microbubble pump effect" may
induce blood vessel expansion and contraction via the volumetric oscillating microbubbles,
resulting in increased transport of IN-administered agents along the perivascular spaces into the
brain parenchyma. The observation that lower pressure was associated with higher amount of
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800CW-BSA delivered by FUSIN suggests that high acoustic pressures can potentially lead to
faster disruption of microbubbles, thereby reducing the microbubble pump effect. It is also
possible that FUS-induced BBB disruption could enhance "two-way trafficking" between brain
and blood as suggested by our previous study, meaning that molecules in the blood circulation
can enter the brain after FUS-BBBD, and meanwhile, molecules in the brain tissue can also be
released into the blood circulation [210]. Thus, we also suspect that higher pressures lead to
higher enhancement of BBB permeability, which may facilitate the release of 800CW-BSA from
the perivascular space into the blood circulation and thus lead to decreased delivery by FUSIN at
higher pressures. Although future studies are needed to better understand the mechanism of
FUSIN delivery, our findings indicate that the mechanism of FUSIN delivery is different from
that of FUS-BBBD.
Among the three Tlag2 evaluated in this study, the accumulated amount of 800CW-BSA in the
mouse brainstem decreased from 0.5 h to 4.0 h post-FUS (Fig. 6.4). This finding is in contrast to
a previous study reporting increasing brain uptake of albumin FUS-BBBD over 24 h [211]. The
level of 800CW-BSA in the brain parenchyma represents a balance between drug delivery into
the brain and its clearance out of the brain. In FUS-BBBD delivery, since albumin has a
relatively long half-life in blood circulation (~19 days) [212], it can be continuously delivered
across the disrupted BBB from the blood circulation as long as the BBB remains open. The
aforementioned previous study observed a continuous increase of brain uptake of albumin over
24 h after FUS-BBBD treatment, suggesting that the delivery rate of albumin across the BBB
was higher than the clearance rate within this time frame [211]. Our finding that the amount of
albumin delivered by FUSIN decreased over a 4.0 h time frame implies that contrary to FUSBBBD, albumin delivered by FUSIN had a higher clearance rate than the delivery rate over this
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time frame. We suspect that because the IN-administered agent was distributed in the
perivascular space, its delivery into the brain parenchyma reached the maximum immediately
after the application of the FUS-induced microbubble pumping effect and then decreased over
time due to brain clearance.
Regarding the biodistribution of FUSIN-delivered agents in different organs, our previous study
showed that IN administration could deliver agents directly from the nose to the brain,
minimizing systemic exposure [184]. This study verified that FUSIN delivery was associated
with low systemic exposure to all major organs except the stomach and intestines (Fig. 6.5).
Those accumulations in the stomach and intestine could be excreted through feces, leading to
minimal systemic toxicity [168]. This finding is consistent with our previous study, which found
that the concentration of IN-administered radiolabeled gold nanoclusters was close to zero in all
major organs except the stomach and intestines [184,213]. Different IN administration
techniques can affect the deposition within the nasal epithelium as well as delivery outcomes.
Nasal drops, as used in this study, have been commonly used for IN administration to mice and
rats [138,214]. This method has the advantage of not involving the insertion of a flexible tube
into the nasal cavity [215]. Liquid drops are placed at the opening of the nostril, allowing the
animal to forcefully sniff the drops into the nasal cavity and reach the posterior part of the cavity
where the olfactory epithelium is located. However, it has the disadvantage that the nasal
formulation can be swallowed by the animal into the digestive system, resulting in the observed
accumulation of 800CW-BSA in the stomach and intestines over time. As mentioned earlier,
those accumulations could potentially be excreted through feces and minimize systemic toxicity.
To prevent the nasal drops from being swallowed, one solution is to seal the esophagus and
insert a breathing tube into the trachea [137,216]. In clinical studies, various nasal devices, such
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as sprays, droppers, and nebulizers, have been designed to target the nasal formulations to the
olfactory region without deposition in the lungs or esophagus [217]. This unique advantage of
FUSIN in minimizing systemic exposure suggests that FUSIN has the potential to improve the
treatment of a broad spectrum of brain diseases by not only enhancing therapeutic agent delivery
to diseased brain sites but also substantially reducing toxicity to other organs. The high
accumulation of 800CW-BSA in the nose and the trigeminal nerve was consistent with our
previous study of FUSIN delivery of gold nanoparticles [184,213]. This finding confirmed that
the 800CW-BSA delivery pathway was mainly via the nose-to-brain route, which was different
from the blood-to-brain route used by FUS-BBBD. The decreased fluorescence intensities in the
nose and trigeminal nerve suggest that 800CW-BSA was cleared from the nose and trigeminal
nerve over time, which can minimize any potential toxicity of the agent to the nose and nerve
tissues.
Our previous study showed that FUSIN delivery of nanoparticles did not induce any change or
damage to the nasal tissue, trigeminal nerves, or the FUS-targeted brainstem [184]. In this study,
we applied different FUS pressures in FUSIN treatment and performed H&E staining of the
brainstems of mice treated with the highest pressure setting (0.70 MPa) and the control mice
without treatment. There was no observable vascular or tissue damage at the FUS-targeted
brainstem region, which confirmed that the FUS parameters used in this study were safe at the
histological level.
This study had several limitations. First, 800CW-BSA was used as a model agent. Future studies
are needed to compare FUSIN delivery of different agents in order to further characterize the
dependence of FUSIN delivery outcomes on agent characteristics such as size, surface charge,
and material. Second, the present study only showed the dependence of FUSIN on acoustic
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pressure. Other FUS parameters (e.g., frequency, pulse length, and pulse repetition frequency),
as well as microbubble characteristics (e.g., resonant frequency, size, and shell properties), may
also be related to FUSIN outcomes and should be studied in the future. Third, this study only
focused on drug delivery to the brainstem. Further research is needed to assess the brain location
dependency of FUSIN by comparing the delivery outcomes of the same agent to different brain
locations. Fourth, the mechanism of FUSIN delivery is not clear. Further study is needed to
provide direct evidence to show how FUSIN works in brain drug delivery.

6.6. Conclusion
FUSIN is a promising technique for brain drug delivery that integrates FUS and microbubbles to
enhance the accumulation of intranasally administered agents at the FUS-targeted brain location.
The current study found that the measured FUSIN delivery outcomes depend on several critical
experimental parameters, including the time interval between IN and FUS, the FUS pressure, and
the sampling time. This study revealed the unique characteristics of FUSIN as a noninvasive,
efficient, and localized brain drug delivery technique with minimal systemic exposure.
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Chapter 7: FUSIN delivery of anti-programmed
cell death-1 antibody to brainstem gliomas
7.1 Abstract
Immune checkpoint inhibitors have great potential for the treatment of glioma; however, their
therapeutic efficacy has been partially limited by their inability to efficiently cross the blood–
brain barrier (BBB). The objective of this study was to evaluate the capability of focused
ultrasound-mediated intranasal brain drug delivery (FUSIN) in achieving locally enhanced
delivery of anti-programmed cell death-ligand 1 antibody (aPD-L1) to the brain. Both wildtype
mice and mice transcranial implanted with GL261 glioma cells at the brainstem were used in this
study. aPD-L1 was labeled with a near-infrared fluorescence dye (IRDye 800CW) and
administered through the nasal route to mice, followed by FUS sonication in the presence of
systemically injected microbubbles. FUSIN enhanced the accumulation of aPD-L1 at the FUStargeted brainstem by an average of 4.03 and 3.74 folds compared with IN administration alone
in the wildtype mice and glioma mice, respectively. Immunohistochemistry staining found aPDL1 was mainly located within the perivascular spaces after IN delivery, while FUSIN further
enhanced the penetration depth and delivery efficiency of aPD-L1 to the brain parenchyma. The
delivered aPD-L1 was found to be colocalized with the tumor cells after FUSIN delivery to the
glioma. These findings suggest that FUSIN is a promising technique for the delivery of immune
checkpoint inhibitors to the brain.
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7.2 Introduction
Immune checkpoint inhibitor (ICI) therapy has proven its great potential in the treatment of
various cancers; however, its application in the treatment of glioma has been disappointing.
Preclinical studies have demonstrated some efficacy against glioma by ICI therapy with antiCTLA-4, anti-PD-1, and/or anti-PD-L1, either as monotherapy or in conjunction with standardof-care treatments [218]. However, as summarized in a recent review article [219], all reported
clinical trials of ICI therapy in glioma patients failed to show superior results compared with the
standard-of-care. Although the underlying mechanisms for the failure remain unclear, the bloodbrain barrier (BBB) is considered to be one of the major obstacles for ICI therapy of glioma. The
BBB that is responsible for maintaining a constant brain microenvironment restricts the entry of
immune checkpoint inhibitors into the brain and limits the efficacy of ICI immunotherapy.
Several strategies have been proposed to enhance the delivery of ICIs across the BBB. One
strategy modified the aPD-L1 by attaching BBB targeting moieties on the antibody, which
facilitated the trans-BBB delivery of systemically injected aPD-L1 by dopamine receptormediated transcytosis [220]. Another study loaded aPD-1 and aCTLA-4 to a polymer-drug
carrier, poly (β-L-malic acid), to enhance their permeability through the BBB by transferrin
receptor (TfR)-mediated transcytosis [221]. Both approaches enhanced ICI delivery to brain
glioma, led to enhanced immune response, and prolonged animal survival. Although promising,
the chemical modifications have two main limitations: the ICIs were delivered to the whole brain
instead of targeting at the glioma and systemic administration of the ICIs led to systemic toxicity
[222]. Besides modifying the ICIs, an ongoing clinical trial delivers ICIs directly into the
surgical resection cavity of recurrent brain glioma (clinicaltrial.gov; NCT03233152), allowing
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direct delivery of ICIs to the tumor. However, this delivery strategy is invasive and the
penetration depth of the delivered ICIs into the surrounding brain tissue is limited [223].
FUS-mediated intranasal delivery (FUSIN) harvests the unique advantages of IN administration
for direct nose-to-brain drug administration with minimized systemic exposure and FUS in
combination with microbubbles for targeted and enhanced delivery to the brain [70,71,96,184].
FUS-induced microbbubble cavitation pushes and pulls on the adjacent blood vessel [74],
generating the hypothesized "microbubble pumping effect". The microbubble pumping effect is
hypothesized to enhance the penetration and accumulation of IN administered drugs. FUSIN has
been utilized to deliver multiple agents, including dextrans, gold nanoparticles, and protein drugs
to the FUS-targeted region with high efficiency and minimized systemic exposure
[70,73,213,224]. The previous work suggests that FUSIN is a promising brain drug delivery
technique that can enhance the delivery efficiency of different agents to different brain regions;
however, no study has been performed to evaluate the potential of FUSIN in the delivery of ICIs
to glioma.
The objective of this study was to demonstrate the potential of FUSIN in noninvasive and
targeted delivery of aPD-L1 to glioma. A near-infrared fluorescent dye (IRDye 800CW) was
conjugated to aPD-L1 (800CW-aPD-L1) for direct visualization of the spatial distribution of
aPD-L1 in ex vivo brain. The IRDye 800CW has low autofluorescence background, making it an
attractive option for antibody labeling. FUSIN delivery of 800CW-aPD-L1 was first evaluated in
wildtype mice, followed by studies using mice with orthotopic implantation of glioma cells
(GL261) at the brainstem. Treatment of brainstem glioma is extremely challenging. The
brainstem connects the brain to the spinal cord and contains densely packed ascending and
descending tracts and nuclei carrying information to and from the brain [7,225]. The brainstem is
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responsible for controlling many pivotal body functions, such as blood pressure, respiration,
swallowing, motor skills, sensory activity, coordination, and walking. The critical anatomic
location and functions of the brainstem hamper the application of invasive techniques for glioma
treatment, such as neurosurgery. Although chemotherapy and/or radiation therapy are more often
used, but rarely curative [226]. Thus, effective delivery techniques that can noninvasively
overcome the BBB is crucial for enhancing the efficacy of ICI therapy for the brainstem gliomas.
This study showed that FUSIN can noninvasively enhance the accumulation of aPD-L1 at the
mouse brainstem in the wildtype mice and the brainstem glioma in the tumor mice. Our findings
suggest that FUSIN is a promising technique for the delivery of ICIs to glioma in the brain.

7.3 Materials and methods
Near-infrared fluorescent dye-labeled anti-PD-L1 antibody
Monoclonal aPD-L1 was obtained from Bio X Cell (West Lebanon, NH) and diluted to 2.4
mg/ml when ready to use. IRDey 800CW with NHS ester was purchased from LI-COR
Biosciences (Lincoln, NE, USA). IRDey 800CW was conjugated to aPD-L1 following the
manufacturer's protocol for labeling high molecular weight proteins (LI-COR Biosciences). In
brief, aPD-L1 was brought to pH 8.5 with 1 M potassium phosphate (pH 9) and mixed with the
dye in a 3:1 dye: aPD-L1 mol/mol ratio. The antibody/dye solution was protected from light and
incubated for 2 h at room temperature. The labeled aPD-L1 was purified using a desalting
column (7000 MWCO, Thermo Scientific, Catalog #: 21329) pre-equilibrated with 1× PBS. The
conjugated aPD-L1 was kept in 4 ºC until further use. The dye-to-protein ratio of the conjugate
was determined according to the manufacturer's protocol (LI-COR Biosciences) by measuring
the absorbance of 800CW-aPD-L1 at 280 nm (A280) and 780 nm (A780) with a UV
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spectrophotometer (UV-2450 Shimadzu, Japan). The conjugate was diluted in a mixture of PBS
and methanol (1:1), and the following formula was used for calculating the dye/protein (D/P in
mol/mol) ratio,

where 0.03 is a correction factor for the absorbance of the IRDye 800CW at 280 nm (equal to
3.0% of its absorbance at 780 nm), while εDye and εProtein are molar extinction coefficients for the
dye and protein, respectively. εDye is 270000 M-1 cm-1 and εProtein is 203000 M-1 cm-1 for a typical
immunoglobulin G antibodies (IgG) in a 1:1 mixture of PBS : Methanol [227].
Confirmation of 800CW-aPD-L1 conjugation by SDS-PAGE
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was performed to
confirm the conjugation of the aPD-L1 with IRDye 800CW. Both aPD-L1 and 800CW-aPD-L1
were diluted to 0.5 mg/ml and prepared for SDS-PAGE. SDS-PAGE is one of the simplest, least
expensive, and most commonly used techniques in antibodies analysis to define the purity. 15 μL
of 800CW-aPD-L1 conjugate was mixed with 5 μL of 4 Laemmli sample buffer. The 10-well 4–
15% Mini-PROTEAN® TGX™ Precast Protein Gels (Bio-Rad, Hercules, CA, USA) were used
to run the SDS-PAGE. 10 μg of the prepared conjugate was loaded to each well on the gel,
electrophoresis was carried out at a constant voltage 100 V for 1 h. The gel was imaged with the
Licor Pearl small animal imaging system (LI-COR Biosciences) using the 800 nm channel, then
stained with coomassie blue safe stain overnight and imaged with ChemiDoc™ MP Imaging
System (Bio-Rad, Hercules, CA, USA) using white light.
800CW-aPD-L1 binding assay
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Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was performed to
confirm the conjugation of the aPD-L1 with IRDye 800CW. Both aPD-L1 and 800CW-aPD-L1
were diluted to 0.5 mg/ml and prepared for SDS-PAGE. SDS-PAGE is one of the simplest, least
expensive, and most commonly used techniques in antibodies analysis to define the purity. 15 μL
of 800CW-aPD-L1 conjugate was mixed with 5 μL of 4 Laemmli sample buffer. The 10-well 4–
15% Mini-PROTEAN® TGX™ Precast Protein Gels (Bio-Rad, Hercules, CA, USA) were used
to run the SDS-PAGE. 10 μg of the prepared conjugate was loaded to each well on the gel,
electrophoresis was carried out at a constant voltage 100 V for 1 h. The gel was imaged with the
Licor Pearl small animal imaging system (LI-COR Biosciences) using the 800 nm channel, then
stained with coomassie blue safe stain overnight and imaged with ChemiDoc™ MP Imaging
System (Bio-Rad, Hercules, CA, USA) using white light.
Animals
All animal procedures were reviewed and approved by the Institutional Animal Care and Use
Committee in accordance with the National Institutes of Health Guidelines for animal research.
Cr.NIH Swiss mice (6–8 weeks, ~25 g body weight, female) were purchased from Charles River
Laboratory (Wilmington, MA, USA). The animals were housed in a room maintained at 22 °C
and 55% relative humidity, with a 12-h/12-h light/dark cycle and access to standard laboratory
chow and water. Both mice without and with glioma implantation were used in this study.
Intracranial tumor model
For the glioma mice, the mouse glioma cell line, GL261 with the expression of the enhanced
green-fluorescence protein (GL261-eGFP), was obtained from Dr. Dinesh Thotala (Washington
University School of Medicine, St. Louis, MO, USA) and cultured in Dulbecco's Modified Eagle
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Medium (DMEM) with Nutrient Mixture F-12 1:1, 10% fetal bovine serum, 1% sodium pyruvate
(Life Technologies, USA) in a 5% CO2 incubator at 37 °C. The absence of mycoplasma in the
culture was confirmed by using the MycoAlertTM Mycoplasma Detection Kit (Lonza, Basel,
Switzerland). Mice were anesthetized and head fixed on a stereotactic frame. A paramedian
incision was made on the scalp, and a 1-mm burr hole was drilled 0.8 mm posterior and 1.0 mm
lateral to the lambda. GL261-eGFP (volume: 2 µL; cell count: 5 x 104) were mixed with
CorningTM Matrigel (Catalog 356231, Corning Life Science, New York, USA) and injected
through the burr hole using a syringe. The burr hole was sealed with bone wax, and the skin
incision was glued together with tissue glue. Post-surgery analgesia was provided by
subcutaneous injection of buprenorphine (0.03 mg/kg in saline twice daily) for 3 days. The
FUSIN (n=5) and IN (n=5) delivery of 800CW-aPD-L1 to the glioma mice was conducted on
day 14 post implantation.
FUSIN treatment
Both wildtype mice and glioma tumor mice were used for FUSIN delivery following a similar
procedure as reported before [228]. Briefly, mice were placed supine under anesthesia. Drops (3
µL each) of 800CW-aPD-L1 were administered to the mouse nose, alternating between the left
and right nostrils every 2 mins. A total of 8 drops (24 µL) were administered to each mouse. The
concentration of the 800CW-aPD-L1 solution was 0.8 mg/mL for wildtype mice and increased to
2.4 mg/ml for the glioma mice to match with the dose used in clinical studies [229–231]. After
IN administration, the mouse head was then stabilized on a stereotaxic frame and hairs on the
head were removed for the FUS treatment. An ultrasound image-guided FUS system (VIFU
2000; Alpinion US Inc., Bothell, WA, USA) consisting of an ultrasound imaging probe (L8-17,
Alpinion, Seoul, Korea) and a FUS transducer (center frequency 1.5 MHz) was use to target the
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FUS at the brainstem under the assistance of a metal grid [126]. Size-isolated microbubbles
(median diameter: 4–5 µm; concentration: ~8×108 #/mL; injection volume: 30 μL) manufactured
in-house [202] were injected through the tail vein, immediately followed by FUS sonication.
FUS sonication was performed at 0.5 h after IN administration using the following parameters:
pressure = 0.43 MPa, pulse length = 6.7 ms, pulse repetition frequency = 5 Hz, and duration = 1
min. Four points located at the corners of a square with a side length of 0.6 mm were treated in
order to enlarge the treatment volume [228]. Mice were transcardially perfused at 1 h post-IN
delivery, which is ~0.5 h after FUS sonication. Mice delivered by IN only were used as the
control and sacrificed at 1 h post-IN delivery.
Ex vivo fluorescence imaging and analysis
After perfusion, the brains were excised and sliced into 2-mm coronal sections using a brain
matrix (RBM-2000C; ASI Instruments, Inc., Warren, MI, USA) and examined by the Licor Pearl
small animal imaging system, with acquisition using the 800 nm channel for 800CW-aPD-L1.
The exposure time for fluorescence imaging was kept the same (30 s) for all groups. The
fluorescence intensity of the brain slices was quantified using the Licor's Image Studio Lite
software.
ELISA quantification of aPD-L1
ELISA quantification of the 800CW-aPD-L1 delivery were performed for the wildtype mice
treated by IN only (n=5) or FUSIN (n=5) to verify the fluorescence quantification by the Licor
Pearl System . After imaging by the Licor Pearl system, the mice brainstem tissues were
collected, weighted and homogenized by adding 1× RIPA buffer at 10× tissue weight. The
homogenized tissues were then centrifuged at 5000 g for 10 mins at 4 °C and the supernatant was
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collected. The protein concentration of the supernatant was measured with BCA assay and
diluted to 1 mg/mL using dilution buffer (0.5%BSA/PBS/0.05%Tw-20). The ELISA standard
was made using the aPD-L1 stock to generate a serial dilutions in the dilution buffer. The ELISA
plates (Thermo Fisher Scientific, Wilmington, DE, USA) were coated with recombinant mouse
PD-L1 protein (Cat. No. PD1-M5251; ACROBiosystems, Beijing, China) at 4°C overnight. The
plates were then washed with 300 µL washing buffer (PBS/0.05%Tw-20) for three times and
blocked with blocking buffer (2%BSA/PBS/0.05%Tw-20) for 1.5 h at room temperature. The
tissue supernatant and the aPD-L1 standards were added to the pre-coated plate and incubated
overnight at 4 °C, followed by adding the polyclonal horseradish peroxidase (HRP)conjugated rabbit anti-rat antibodies (rabbit anti-rat, Jackson ImmunoResearch, West Grove, PA)
and incubated for 1.5 h at room temperature. After the incubation, the plates were washed and
added with 90 µl TBM substrates for 10 mins, followed by 50 µl stop buffer. Data was acquired
with SpectraMax® i3 Platform (Molecular Devices LLC, San Jose, CA, USA). The concentration
of 800CW-aPD-L1 in brainstem tissue samples was calculated in reference to the 800CW-aPDL1 standard curve.
Immunostaining
In order to further study the microscopic level distributions of 800CW-aPD-L1 after FUSIN, the
brainstem of wildtype mice after FUSIN were harvested and immunofluorescence stained for
aquaporin 4 (AQP4), the blood vessel, and the aPD-L1. AQP4 is the most prevalent aquaporin
channel specifically located at the perimicrovessel astrocytic endfeet and aligned with the
perivascular space. The brainstems of tumor mice were also harvested and immunofluorescence
stained for aPD-L1 to image the spatial distribution of the deliverd aPD-L1. All the brain
samples were fixed in 4% paraformaldehyde (PFA) overnight and equilibrated in 30% sucrose
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for cryosectioning. The fixed brainstems were sectioned to 20 µm slices using Leica CM3050 S
cryostat (Leica Biosystems). The slices were preprocessed in 0.3% v/v Triton X-100 and 3% v/v
blocking serum solution in PBS for 1 h in the dark at room temperature to increase the
permeability and block the background, then washed using PBS. For the wildtype mice, the
slices were incubated in an anti-aquaporin4 antibody (anti-AQP4) (Alomome Lab, Cat: AQP004, 1:200) solution overnight at 4 °C, washed with PBS, and then incubated in Alexa Fluor 594
AffiniPure donkey anti-rat IgG (H+L) (Jackson immunoResearch, Cat: 712-585-153, 1:400)
overnight at 4 °C for staining aPD-L1. After that, the slices were added with DyLight 649labeled tomato lectin (Vector Laboratories, Cat: DL-1178-1, 1:1000) and incubated in the dark
for 2 hs at room temperature. Finally, the slices were mounted with VECTASHIELD antifade
mouFIting media (Vector Laboratories, Cat: H-1000). For the tumor mice, the slices were only
stained with Alexa Fluor 594 AffiniPure donkey anti-rat IgG (H+L) following the same
procedure mentioned above.
Statistical analysis
Statistical analysis was performed using GraphPad Prism (Version 8.3, La Jolla, CA, USA).
Differences between the two groups (IN vs. FUSIN) were determined using an unpaired twotailed Student's t-test. A p-value < 0.05 was used to determine statistical significance.

7.4 Results
Characterization of the 800CW-aPD-L1
The 800CW-aPD-L1 conjugation (Fig. 7.1A) had an average of 2.7 molecules of 800CW dye per
a single molecule of aPD-L1 as determined by the UV spectrophotometer (Fig. 7.1B). Single
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band of 800CW-aPD-L1 conjugate at MW of ~150 kDa was detected by both coomassie blue
staining and near-infrade fluorescence imaging, indicating that the 800CW dye labeling did not
causing any degradation or alter the size of the aPD-L1. The flow cytometry analysis showed
that both 800CW-aPD-L1 and aPD-L1 were binded to the GL261 cells at similar binding
efficiency (Fig. 7.1D), indicating the 800CW fluorescence labeling would not affect the
capability of aPD-L1 binding to the tumor cells.

Figure 7. 1: Analysis of 800CW-aPD-L1 conjugates. (A) Schematics illustration of 800CW conjugated to
aPD-L1 through NHS ester reaction. (B) Absorbance spectrum of 800CW-aPD-L1 measured by the UV
spectrophotometer. (C) SDS-PAGE of aPD-L1 and 800CW-aPD-L1 by both coomassie blue staining and
fluorescence imaging. (D) Flow cytometry analysis of binding affinity of aPD-L1 and 800CW-aPD-L1 to
GL261 cells with high surface PD-L1 expression..
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FUSIN delivery of the 800CW-aPD-L1 to the wild type mice
Representative fluorescence images of the mouse brain slices from the wildtype mice and the
quantification of the delivery efficiencies are presented in Figure 7.2. The top slice contained the
olfactory bulb. Enhanced fluorescence intensity was observed in the top slices for both FUSIN
and IN groups, confirming successful IN administration of the 800CW-aPD-L1. The bottom two
slices contained the brainstem. The fluorescence intensity of the bottom two slices from the
FUSIN group was significantly higher than those from the IN groups. Based on the fluorescence
quantification, the delivery efficiency of FUSIN to the brainstem was found to be on average
4.03-fold higher than that of IN only (p<0.05). Moreover, the ELISA quantification of the same
brainstem slices found a strong linear correlation between the concentration of the 800CW-aPDL1 and the fluorescence intensity (Fig.7.2C), indicating that the fluorescence intensity can be
used as a surrogate for quantifying the delivery efficiency of the 800CW-aPD-L1.
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Figure 7. 2: FUSIN delivery of 800CW-aPD-L1 to brainstem. (A) Fluorescence images of representative
ex vivo mouse brain slices. The olfactory (Olf) bulb is in the top slice. The targeted location of the FUS
was located at the right side of the brainstem. The dashed box highlights the brain slices containing the
brainstem. (B) Fluorescence quantification of the 800CW-aPD-L1 delivery efficiency to the brainstem.
(C) The relationship between the fluorescent intensity measured by ex vivo fluorescence imaging and the
aPD-L1 concentrations measured by ELISA.
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Figure 7.3 shows the representative images at the microscopic level of mice brain sections after
FUSIN delivery. After IN delivery, the aPD-L1 is observed between the blood vessel and the
AQP4, indicating that the IN delivered aPD-L1 were traveling along the perivascular space.
After FUSIN delivery, enhanced accumulation of of aPD-L1 was observed and the aPD-L1 was
not only located within the perivascular space but also deep penetrated into the brain
parenchyma.

Figure 7. 3: Fluorescence images of the brainstem obtained from wildtype mice after IN (A) and FUSIN
(B) delivery. After IN delivery, immunofluorescence staining shows the aPD-L1 distributed along the
perivascular space, defined by the space between the AQP4-stained astrocyte and the lectin-stained blood
vessel. FUSIN enhanced the accumulation of aPD-L1 and the delivered aPD-L1 penetrated deep into the
brain parenchyma.

FUSIN delivery to the tumor mice
Figure 7.4A shows representative fluorescence images and the corresponding photographs of the
mouse brain slices of mice with brainstem gliomas. The brainstem, where the glioma was
implanted, showed enhanced fluorescence signal by FUSIN compared with IN only. The location
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of the glioma is pointed out by the arrow. At lower magnification (2×), the aPD-L1 was observed
in the FUS-targeted right side of the brainstem and locally accumulated within the glioma
growing on the right side of the brainstem. At a higher magnification (60×), the aPD-L1 were
found to be colocalized with the tumor cells, suggesting the delievered aPD-L1 was bound to the
tumor cells. The quantification of the delivery efficiency is presented in Figure 7.4C. The
delivery efficiency of FUSIN was found to be on average 3.74-fold higher than that of IN only to
the brainstem (p<0.01).
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Figure 7. 4: FUSIN delivery of 800CW-aPD-L1 to brainstem glioma. (A) Fluorescence images of
representative ex vivo mouse brainstem slices. The white arrow indicted the tumor locatoin. (B) Spatial
distribution of FUSIN-delivered 800CW-aPD-L1. Left panel: aPD-L1 distribution in a coronal section of
the brainstem after FUSIN delivery imaged at 2×. Right panel: higher magnification view (60×) of the
tumor showing the colocalization of aPD-L1 with the tumor cells. (C) Fluorescence quantification of the
800CW-aPD-L1 delivery efficiency to brainstem glioma.

7.5 Discussion
Efficient delivery of ICIs is critical for ICI therapy of glioma. Although the glioma immune
microenvironment is very complex, it has been demonestretd the treatment efficacy of mice with
gliomas could be significantly increased by enhancing the delivery of ICIs across the BBB
[220,221]. Efficient delivery of ICIs to brain glioma is expected to directly disrupt the PD-1/PDL1 or CTLA-4/B7-1 complex formation in the tumor, resulting in activation of brain local
inmmune response and leading to improved survival of glioma mice [232]. A previous study
chemically modified the aPD-L1 for receptor mediated transcytosis delivery across the BBB
[220]. That study achieved 2-fold increase of aPD-L1 delivery compared to aPD-L1 without
modification in the GL261 mouse model after intravenously injection and significantly improved
the mouse surivival. In the current study, aPD-L1 was labled by an near-infrared fluorescent dye.
The low autofluorescence background of the dye and the stable labeling provide unique strengths
for evaluating the delivery outcome of aPD-L1 by FUSIN. Using the 800CW-aPD-L1, we found
that the delivery efficiency of FUSIN was in an average 4.03 fold higher in wildtype mice and
3.74 fold higher in glioma mice when compared to IN delivery only. This is the first study that
applied FUSIN in a mouse model of glioma. The finding that the enhancement ratios were
comparable for wildtype mice and tumor mice suggest that the enhancement effect of FUSIN is
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not affected by the tumor microenvironment. Future study needs to examine the corresponding
immune response and treatment efficacy to demonstrate the therapeutic benefits fo FUSIN
delivery of aPD-L1.
The mechanism of FUSIN delivery is still under investigation. The olfactory nerve and
trigeminal nerve ending in the nose cavity provide a route for direct medication delivery into the
brain in nose-to-brain delivery. Bulk transport along the channels surrounding the olfactory and
trigeminal nerves is the most likely mechanism for nose-to-brain transport based on the rapid
speed of transport from the nose to brain [145]. Once inside the brain entry points (i.e., olfactory
bulb and brainstem), the IN administered agents are distributed in the whole brain along the
cerebral perivascular space and propelled through the perivascular spaces by heartbeat-driven
pulsations of the blood vessel walls, called the perivascular pump effect [138]. Previous IN
delivery of IgG were observed in the perivascular space, supporting that perivascular space is the
potential transporting pathways for brain distribution of intranasally-administered antibodies
[26,27]. This study showed similar results in brainstem after IN administration of aPD-L1
without FUS treatment, confirming that the IN delivered aPD-L1 were distributed along the
perivascular space (Fig. 7.3A). While, on the FUS treated brainstem, the accumulation and the
penetration of the aPD-L1 were boosted (Fig. 7.3B). Our previous work on ultra-high-speed
photomicrography of microbubble dynamics in ex vivo microvessels observed that microbubble
oscillations push and pull on the blood vessel, leading to expansion and contraction of the vessel
and surrounding tissues [74]. Based on the similarity of this phenomenon with the perivascular
pump effect, we hypothesized that the “microbubble pump effect” may be the potential
mechanism for FUSIN. The microbubble pump could increase the bulk flow in the perivascular
space and even the surrounding interstitial fluid, enhancing convective transport. Meanwhile, as
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IN delivered aPD-L1 trasporated away from the perivascular space to the brain parenchyma at
the FUS-targeted region, the concentration of the aPD-L1 in the perivascular space within the
targeted region would decrease and the aPD-L1 in the perivascular space outside the FUS
targeted region may flow into the targeted region driven by the concentration gradient, leading to
locally enhanced accumulation of IN-administered a-PD-L1 at the FUS-targeted region. The
mechanism of FUSIN warrants further investigation.

7.6. Conclusion
In this study, aPD-L1 was fluorescently labeled by the IRDye 800CW and used to evaluate the
potential of FUSIN in the ICI delivery to both wildtype mice and glioma mice. The labeling did
not alter the binding affinity of aPD-L1 with PD-L1 protein and enalbes the quantification of the
spatial distribution of aPD-L1 delivery by fluorescent imaging. FUSIN achieved significantly
enhanced delivery of aPD-L1 to the brainstem of wildtype mice and brainstem glioma in tumor
mice. The deliverd aPD-L1 penetrated deep into the brain parenchyma at FUSIN-targeted
brainstem with high local accumulation. The delivered aPD-L1 was also found to bind to the
tumor cells when delivered to the brainstem gliomas. These findings suggest that FUSIN is a
promising technique to facilitate the delivery of immune checkpoint inhibitors to the brain.
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Chapter 8: Conclusions and future perspectives
8.1 Conclusion
In this thesis, two FUS mediate brain drug delivery techniques: focused ultrasound induced
blood-brain barrier disruption (FUS-BBBD) and focused ultrasound combined with
microbubble-mediated intranasal (FUSIN), were studied and evaluated for drug delivery to the
brainstem. Both of those two techniques achieved the non-invasive and localized delivery to the
brainstem and brainstem gliomas. By comparing those two techniques for delivering the TRAuNCs to the brainstem, FUSIN showed a clear advantage over FUS-BBBD for reduced
systemic exposure and increased the delivery efficiency.
Furthermore, we evaluated the effect of several key experimental conditions for FUSIN drug
delivery to help us further improve the efficiency of FUSIN. We found that drug delivery
outcome by FUSIN in the brainstem depends on, but not limited to, the time delay between IN
and FUS, the FUS pressure, and the waiting time to sacrifice the mouse post-FUS. Those
findings provided insights for selecting optimal treatment parameters for FUSIN delivery, such
like considering the kinetics of drug distribution in different brain regions to adjust the time
interval between administration and ultrasound to optimize the delivery efficiency. Those
findings also provided insights on the potential mechanisms of FUSIN.

8.2 Perspectives
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FUS-BBBD has been developed for two decades. Comprehensive studies have been done for
evaluated its feasibility of delivery various drugs for treating several neurological diseases, as
well as its safety. Recently, the clinical trials of FUS-BBBD is gradually on going in US,
Canada, France etc. for people having neurodegeneration diseases or brain tumor. Our work
paved the way for extending FUS-BBBD delivery, which was mainly concentrating on the
cerebral diseases, to the brainstem. We also suspected pediatric patients with the brainstem
gliomas can also benefit from this technique.
FUSIN was first reported in 2014 (Chen et al. 2014) for delivery a dextran to the caudate
putamen. In this thesis, we not only proved FUSIN delivery is also applicable in brainstem and
brainstem gliomas, confirmed it is a universal brain drug delivery method; but also showed
FUSIN, compared to the FUS-BBBD can significantly reduce the systemic exposure, which
could benefit bunch of drugs whose therapeutic efficacy is limited by their toxicity. This is a big
step forward for drugs treating the CNS diseases but have toxic side effects. Moreover, the 20fold increased drug delivery efficiency of the AuNCs by FUSIN than by FUS-BBBD also
demonstrates its superiority over FUS-BBBD for brainstem delivery. It worth to point out
FUSIN is different from FUS-BBBD as the nose-to-brain pathway is more selective, thus, nasal
barrier might be a problem for FUSIN delivery. We suggested FUSIN can be a promising brain
drug delivery tool to be applied for drugs which is in the IN delivery market, such as antibody,
peptides, nanocarriers (liposomes, AuNPs etc), and some chemotherapeutics. The effects of drug
properties, such as hydrodynamic size, charge and PH etc. on the delivery outcome need to be
further explored.
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